Skip to main content
SpringerLink
Log in

Viral Infections in Patients with Hematological Malignancies

  • Chapter
  • First Online:
Neoplastic Diseases of the Blood

  • 2746 Accesses

Abstract

Enormous advances in the control of bacterial and fungal pathogens have occurred over the last decade. Although host factors such as impairment of granulocyte function or impaired mucosal barrier integrity are major risk factors for bacterial and fungal pathogens, compromise of cell-mediated immunity, especially of cytotoxic thymus-derived lymphocytes (T cells), appears to be most significant in accounting for susceptibility to viral pathogens. As dose intensity of the chemotherapeutic regimens used in the therapy of hematological malignancies has escalated over the last decade, greater susceptibility to viral pathogens has emerged.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Muller SA, Herrman Jr EC, Winkelmann RK. Herpes simplex infections in hematologic malignancies. Am J Med. 1972;52:102.

    Article  PubMed  CAS  Google Scholar 

  2. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 1980;142:338.

    Article  PubMed  CAS  Google Scholar 

  3. Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med. 1981;305:63.

    Article  PubMed  CAS  Google Scholar 

  4. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients. A randomized, double-blind placebo controlled study. Ann Intern Med. 1983;99:773.

    PubMed  CAS  Google Scholar 

  5. Anderson H, Scarfee JH, Sutton RNP, Hickmott E, Brigden D, Burke C. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind placebo controlled trial. Br J Cancer. 1984;50:45–9.

    Article  PubMed  CAS  Google Scholar 

  6. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest. 1980;65: 869–78.

    Article  PubMed  CAS  Google Scholar 

  7. Rand K, Kramer A, Johnson A. Cancer chemotherapy associated symptomatic stomatitis. Role of herpes simplex virus. Cancer. 1982;50:1262–5.

    Article  PubMed  CAS  Google Scholar 

  8. Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE. Effect of acyclovir on radiation and chemotherapy-induced mouth lesions. Antimicrob Agents Chemother. 1989;33:862–5.

    Article  PubMed  CAS  Google Scholar 

  9. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, editors. Clinical approaches to infection in the compromised host. 2nd ed. New York: Plenum; 1988. p. 525.

    Chapter  Google Scholar 

  10. Wingard JR. Infectious and noninfectious systemic consequences. Oral complications of cancer therapies. Diagnosis, prevention, and treatment. NCI Monogr. 1990;9:21–6.

    PubMed  Google Scholar 

  11. Weiden PL, Schuffler MD. Herpes esophagitis complicating Hodgkin’s disease. Cancer. 1974;33:1100.

    Article  PubMed  CAS  Google Scholar 

  12. McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology. 1985;88:1111–7.

    PubMed  CAS  Google Scholar 

  13. Lynfield YL, Farhangi M, Runnels JL. Generalized herpes simplex complicating lymphoma. JAMA. 1969;207:944.

    Article  PubMed  CAS  Google Scholar 

  14. Buss DH, Scharyj M. Herpesvirus infection of the esophagus and other visceral organs in adults. Am J Med. 1979;66:457–62.

    Article  PubMed  CAS  Google Scholar 

  15. Elfenbein GJ, Saral R. Infectious disease during immune recovery after bone marrow transplantation. In: Allen JC, editor. Infection and the compromised host. Baltimore: Williams & Wilkins; 1981. p. 167–96.

    Google Scholar 

  16. Skolnick D, Bustamante CI, Saltzberg D, et al. Diagnosis of esophagitis in immunocompromised patients. A prospective evaluation. In: Program and abstracts of the 27th interscience conference on antimicrobial agents and chemotherapy. New York, October 4–7, 1987, Abstract 954. Washington, DC: American Society of Microbiology; 1987, p. 263.

    Google Scholar 

  17. Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis due to herpes simplex virus in marrow transplant recipients. Clin Infect Dis. 1992;14:38–45.

    Article  PubMed  CAS  Google Scholar 

  18. Ramsey PG, Fife FH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia. Ann Intern Med. 1982;97:813–20.

    PubMed  CAS  Google Scholar 

  19. Becker WB, Kipps A, McKenzie D. Disseminated herpes simplex virus infection. Am J Dis Child. 1968;115:1.

    PubMed  CAS  Google Scholar 

  20. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years’ experience. Rev Infect Dis. 1982;4:1119–32.

    Article  PubMed  CAS  Google Scholar 

  21. Pruneda RC, Almanza I. Centrifugation-shell vial technique for rapid detection of herpes simplex virus cytopathic effect in vero cells. J Clin Microbiol. 1987;25:423.

    PubMed  CAS  Google Scholar 

  22. Schmidt NJ, Dennis J, Devlin V, Callo D, Mills J. Comparison of direct immunofluorescence and direct immunoperoxidase procedures for detection of herpes simplex virus antigen in lesion specimens. J Clin Microbiol. 1983;18:445–8.

    PubMed  CAS  Google Scholar 

  23. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med. 1986;314(686–691):749–57.

    Article  PubMed  CAS  Google Scholar 

  24. Gonik B, Seibel M, Berkowitz A, Woodin MB, Mills K. Comparison of two enzyme-linked immunosorbent assays for detection of herpes simplex virus antigen. J Clin Microbiol. 1991;29:436–8.

    PubMed  CAS  Google Scholar 

  25. Nahass GT, Goldstein BA, Zhu WY, Serfing NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnosis methods in detection of herpes simplex and varicella-zoster infection. JAMA. 1992;268:2541–4.

    Article  PubMed  CAS  Google Scholar 

  26. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for the treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982;73A:229.

    Article  Google Scholar 

  27. Mitchell CD, Gentry SR, Boen JR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet. 1981;2:1389.

    Article  Google Scholar 

  28. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;100:823–8.

    PubMed  CAS  Google Scholar 

  29. Shepp DH, Newton BA, Dandliker PS, et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. Ann Intern Med. 1985;102:783.

    PubMed  CAS  Google Scholar 

  30. Wade JC, Newton B, McLaren C, et al. Treatment of mucocutaneous herpes simplex virus infection after marrow transplantation with intravenous acyclovir. A double blind trial. Ann Intern Med. 1982;96:265.

    PubMed  CAS  Google Scholar 

  31. Selby PJ, Jameson B, Watson JG, et al. Parenteral acyclovir therapy for herpes virus infections in man. Lancet. 1980;2:1267.

    Google Scholar 

  32. Wade JC, Newton B, Flournoy N, et al. Acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;99:773–6.

    Google Scholar 

  33. Wade JC, Meyers JD. Neurological symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med. 1983;98:921.

    PubMed  CAS  Google Scholar 

  34. Krigel RL. Reversible neurotoxicity due to oral acyclovir in patient with chronic lymphocytic leukemia. J Infect Dis. 1986; 154:189.

    Article  PubMed  CAS  Google Scholar 

  35. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759–64.

    Article  PubMed  CAS  Google Scholar 

  36. Perry CM, Faulds D. Valaciclovir. A review of its antiviral, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52:754–72.

    Article  PubMed  CAS  Google Scholar 

  37. Weller S, Blum R, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595–605.

    Article  PubMed  CAS  Google Scholar 

  38. Saral R. Management of acute viral infections. NCI Monogr. 1990;9:107–10.

    PubMed  Google Scholar 

  39. Wingard JR. Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphoma. 1993;11:115–25.

    Article  PubMed  Google Scholar 

  40. Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis. 1983;148:1077–82.

    Article  PubMed  CAS  Google Scholar 

  41. Ambinder RF, Burns WH, Lietman PS, et al. Prophylaxis. A strategy to minimize antiviral resistance. Lancet. 1984;1:1154–5.

    Article  PubMed  CAS  Google Scholar 

  42. Burns WH, Santos GW, Saral R, et al. Isolation and characterizations of resistant herpes simplex virus after acyclovir therapy. Lancet. 1982;2:421.

    Article  Google Scholar 

  43. McLaren C, Chen MS, Ghazzouli I, Saral R, Burns WH. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agent Chemother. 1985;28:740–4.

    Article  CAS  Google Scholar 

  44. Ljungman P, Ellis MN, Hackman RC, et al. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990;162:244.

    Article  PubMed  CAS  Google Scholar 

  45. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med. 1989;111:893–9.

    PubMed  CAS  Google Scholar 

  46. Whitley RJ, Gnann JW. Acyclovir. A decade later. N Engl J Med. 1992;327:782–9.

    Article  PubMed  CAS  Google Scholar 

  47. Chakrabarti S, Pillay D, Ratcliffe D, et al. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients. risk factors and prognostic significance. J Infect Dis. 2000;181:2055–8.

    Article  PubMed  CAS  Google Scholar 

  48. Safrin S, Assakeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients. Preliminary data. J Infect Dis. 1990;161:1078.

    Article  PubMed  CAS  Google Scholar 

  49. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:551–5.

    Article  PubMed  CAS  Google Scholar 

  50. Wu X, Wang Y, Xu Y, et al. Cytomegalovirus glycoprotein B genotype in hematopoietic stem cell transplant patients from China. Biol Blood Marrow Transplant. 2010;16(5):647–52.

    Article  PubMed  CAS  Google Scholar 

  51. Torok-Storb B, Boeckh M, Hoy C, et al. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood. 1997;90:2097–102.

    PubMed  CAS  Google Scholar 

  52. Fries BC, Chou S, Boeckh M, et al. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis. 1994;169:769–74.

    Article  PubMed  CAS  Google Scholar 

  53. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78:246–50.

    PubMed  CAS  Google Scholar 

  54. De Witte T, Schattenbereg A, Van Dijk BA, Galama J, Olthuis H, Van Der Meer JWW, Kunst VAJM. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation. 1990;50:964–8.

    Article  PubMed  Google Scholar 

  55. Winston DJ, Ho WG, Howell CL, et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med. 1980;93:671.

    PubMed  CAS  Google Scholar 

  56. Wingard JR, Piantadosi S, Burns WH, et al. Cytomegalovirus infections in patients treated by intensive cytoreductive therapy with marrow transplant. Rev Infect Dis. 1990;12 Suppl 7:S805–10.

    Google Scholar 

  57. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1990;12 Suppl 7:S776–92.

    Article  PubMed  Google Scholar 

  58. Hutza AST, Muhl E, Hackstein H, et al. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis. 1998;26:1076–82.

    Article  Google Scholar 

  59. Ho M. Editorial response. Cytomegalovirus infection in patients with bacterial sepsis. Clin Infect Dis. 1998;26:1083–4.

    Article  PubMed  CAS  Google Scholar 

  60. Henson D, Siegel SE, Fucillo DA, et al. Cytomegalovirus infections during acute childhood leukemia. J Infect Dis. 1972;126:469.

    Article  PubMed  CAS  Google Scholar 

  61. Vaughan WP, Saral R, Anderson LR, Burke PJ. The frequency and pattern of cytomegalovirus (CMV) infection and shedding by patients who have received high dose times-sequential chemotherapy (TSC) for acute myelocytic leukemia (AML). Proceedings of the 17th annual meeting of the American Society of Clinical Oncology, Washington, DC, April 30–May 2, 1981; p. 170, Abstract 673.

    Google Scholar 

  62. Wade JC, Bustamante CI, Newman KA, Devlin AM. Cytomegalovirus. An important pathogen for adults receiving induction therapy for acute leukemia. Presented at 28th annual interscience conference on antimicrobial agents and chemotherapy, Los Angeles, October 23–26, 1988, Abstract 1394.

    Google Scholar 

  63. Zaia JA, Forman SJ, Ting Y-P, Vanderwal-Urbina E, Blume KG. Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients. J Infect Dis. 1986;153:780–7.

    Article  PubMed  CAS  Google Scholar 

  64. Einsele H, Ehninger G, Steidle M, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood. 1993;82:1672–8.

    PubMed  CAS  Google Scholar 

  65. Quinan Jr GV, Kirmani N, Rook AH, et al. Cytotoxic cells in cytomegalovirus infections. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med. 1982;307:7.

    Article  Google Scholar 

  66. Reusser P, Riddel SR, Meyers SD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation. Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1992;78:1373–80.

    Google Scholar 

  67. Quinnan Jr GV, Burns WH, Kirmani N, et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis. 1984;6:156–63.

    Article  PubMed  Google Scholar 

  68. Reusser P, Attenhofer R, Hebart H, et al. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood. 1997;89:3873–9.

    PubMed  CAS  Google Scholar 

  69. Shanley JD. Murine cytomegalovirus pneumonitis in T cell deficient nude mice. In Abstracts of the 12th Herpesvirus Workshop, Philadelphia, 1987.

    Google Scholar 

  70. Grundy JE, Shanley JD, Shearer GM. Augmentation of graft versus host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation. 1985;39:548–53.

    Article  PubMed  CAS  Google Scholar 

  71. Shanley JD, Pesanti EL, Nugent KM. The pathogenesis of pneumonitis due to murine cytomegalovirus. J Infect Dis. 1982;146: 388–96.

    Article  PubMed  CAS  Google Scholar 

  72. Shanley JD, Pomeroy C, Via CS, Shearer GM. Interstitial pneumonitis during murine cytomegalovirus infection and graft-versus-host reaction. Effect of ganciclovir therapy. J Infect Dis. 1988;158:1391–4.

    Article  PubMed  CAS  Google Scholar 

  73. Shanley JD, Pesanti EL. The relation of viral replication to ­interstitial pneumonitis in murine cytomegalovirus lung infection. J Infect Dis. 1985;151:454–8.

    Article  PubMed  CAS  Google Scholar 

  74. Appelbaum FR, Meyers JD, Fefer A, et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation. 1982;46:61–5.

    Google Scholar 

  75. Wingard JR, Chen DY-H, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation. Comparison to infection after allogeneic bone marrow transplantation. Blood. 1988;71:1432–7.

    PubMed  CAS  Google Scholar 

  76. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation. Occurrence of cytomegalovirus disease and effect on engraftment. Blood. 1990;75:1888–94.

    PubMed  CAS  Google Scholar 

  77. Ljungman P, Biron P, Bosi A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplant. 1994;13:209–12.

    PubMed  CAS  Google Scholar 

  78. Wingard JR, Sostrin MB, Vriesendorp HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1988;46:61–5.

    Article  PubMed  CAS  Google Scholar 

  79. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation. 1993;55: 1339–46.

    Article  PubMed  CAS  Google Scholar 

  80. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–88.

    Article  PubMed  CAS  Google Scholar 

  81. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after marrow transplantation. An association with acute graftversus-host-disease. Blood. 1986;67:1161–7.

    Google Scholar 

  82. Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med. 1986;104:168–75.

    PubMed  CAS  Google Scholar 

  83. Wingard JR, Mellits ED, Sostrin MB, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore). 1988;67: 175–86.

    CAS  Google Scholar 

  84. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation. Importance of cytomegalovirus viremia. J Infect Dis. 1988;162:373–80.

    Article  Google Scholar 

  85. Paulin T, Ringden O, Lönnqvist B, Wahren B, Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. Analysis of risk factors. Scand J Infect Dis. 1986;18:199–209.

    Article  PubMed  CAS  Google Scholar 

  86. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N Engl J Med. 1991;324:1005–11.

    Article  PubMed  CAS  Google Scholar 

  87. Slavin M, Gooley TA, Bowden RA. Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid. Transplantation. 1994;58:915–9.

    Article  PubMed  CAS  Google Scholar 

  88. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240–5.

    PubMed  CAS  Google Scholar 

  89. Ljungman PT, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serological status and outcome of CMV seropositive recipients after unrelated donor stem cell transplantation. an EBMT megafile analysis. Blood. 2003;102: 4255–60.

    Article  PubMed  CAS  Google Scholar 

  90. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors. evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–82.

    Article  PubMed  Google Scholar 

  91. Alessandrino EP, Varettoni M, Colombo AA, et al. High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2000;95:4016–7.

    PubMed  CAS  Google Scholar 

  92. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999;94:4029–35.

    PubMed  CAS  Google Scholar 

  93. Schiller GJ, Vescio R, Berenson J. Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells. Blood. 2000;96:1194.

    PubMed  CAS  Google Scholar 

  94. Gregory WW, Menegus MA. Practical protocol for cytomegalovirus isolation. Use of MRC-5 cell monolayers incubated for 2 weeks. J Clin Microbiol. 1983;17:605–9.

    PubMed  CAS  Google Scholar 

  95. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol. 1984;19:917–9.

    PubMed  CAS  Google Scholar 

  96. Leland DS, Hansing RL, French ML. Clinical experiences with cytomegalovirus isolation using conventional cell cultures and early antigen detection in centrifugation-enhanced shell vial cultures. J Clin Microbiol. 1989;27:1159–62.

    PubMed  CAS  Google Scholar 

  97. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985;21:217.

    PubMed  CAS  Google Scholar 

  98. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80: 1358–64.

    PubMed  CAS  Google Scholar 

  99. Van der Bij W, Torensma R, van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol. 1988;25:179–88.

    Article  PubMed  Google Scholar 

  100. Jiwa NM, van de Rijke FM, Mulder A, et al. An improved immunocytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry. 1989;91:345–9.

    Article  PubMed  CAS  Google Scholar 

  101. Spector SA, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol. 1992;30:2359–65.

    PubMed  CAS  Google Scholar 

  102. Brytting M, Xu W, Wahren B, et al. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol. 1992;30:1937–41.

    PubMed  CAS  Google Scholar 

  103. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood. 1991;77:1104–10.

    PubMed  CAS  Google Scholar 

  104. Nolte FS, Emmens RK, Thurmond C, Mitchell PS, Pascuzzi C, Devine SM, Saral R, Wingard JR. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol. 1995;33:1263–6.

    PubMed  CAS  Google Scholar 

  105. Landry ML, Fergussen D. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol. 1993;31:2851–6.

    PubMed  CAS  Google Scholar 

  106. Schmidt CA, Oettle H, Wilborn F, Jessen J, Timm H, Schwerdtfeger R, Oertal J, Siegert W. Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant. 1994;13:71–5.

    PubMed  CAS  Google Scholar 

  107. Hackman RC, Wolford JL, Gleaves CA, Myerson D, Beauchamp MD, Meyers JD, McDonald GB. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. Transplantation. 1994;57:231–7.

    Article  PubMed  CAS  Google Scholar 

  108. Crawford SW, Bowden RA, Hackman RC, et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1988;108: 180–5.

    PubMed  CAS  Google Scholar 

  109. Meyers JD, McGuffin RW, Bryson YJ, Cantell K, Thomas ED. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis. 1982;146:80–4.

    Article  PubMed  CAS  Google Scholar 

  110. Wade JC, Hintz M, McGuffin RW, et al. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med. 1982;73A:249.

    Article  Google Scholar 

  111. Wade JC, McGuffin RW, Springmeyer SC, Newton B, Singer JW, Meyers JD. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis. 1993;148:557–62.

    Article  Google Scholar 

  112. Meyers JD, Flournoy N, Sanders JE, et al. Prophylactic human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med. 1987;107:809.

    PubMed  CAS  Google Scholar 

  113. Reed EC, Bowden RA, Dandliker PS, et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis. 1987;156:641.

    Article  PubMed  CAS  Google Scholar 

  114. Shepp DH, Dandliker PS, deMiranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985;103:368.

    PubMed  CAS  Google Scholar 

  115. Reed EC, Dandliker PS, Meyers JD. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl] guanine and high dose corticosteroids. Ann Intern Med. 1986;105:214–6.

    PubMed  CAS  Google Scholar 

  116. Bratanow NC, Ash RC, Turner PA. Successful treatment of serious cytomegalovirus (CMV) disease with 9-(1,3-dihydroxy-2propoxymethyl)guanine (ganciclovir), DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients. Exp Hematol. 1987;15:541 (abstract no. 254).

    Google Scholar 

  117. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–82.

    PubMed  CAS  Google Scholar 

  118. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–8.

    PubMed  CAS  Google Scholar 

  119. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation. 1988;46:905–7.

    Article  PubMed  CAS  Google Scholar 

  120. Ljungman P, De Bock R, Cordonnier C, et al. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients. A report from the Working Party for Infectious Diseases of the EBMT. Bone Marrow Transplant. 1993;12:399–403.

    PubMed  CAS  Google Scholar 

  121. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med. 1990;112:505–10.

    PubMed  CAS  Google Scholar 

  122. Ljungman P, Cordonnier C, Einsele H, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients. A report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Blood Marrow Transplant. 1998;21:473–6.

    Article  CAS  Google Scholar 

  123. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas D, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314: 1006–10.

    Article  PubMed  CAS  Google Scholar 

  124. Mackinnon S, Burnett AK, Crawford RJ, Cameron S, Leask BGS, Sommerville RG. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol. 1988;41:948–50.

    Article  PubMed  CAS  Google Scholar 

  125. Miller W, McCullough J, Balfour HH, et al. Prevention of CMV infection by blood products. A randomized trial. J Cell Biochem. 1988;12(Suppl C):93 (abstract no. K128).

    Google Scholar 

  126. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598–603.

    PubMed  CAS  Google Scholar 

  127. Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12–8.

    PubMed  CAS  Google Scholar 

  128. Bass EB, Powe NR, Goodman SN, et al. Efficacy of Intravenous immune globulin in preventing complications of bone marrow transplantation. A meta analysis. Bone Marrow Transplant. 1993;12:273–82.

    PubMed  CAS  Google Scholar 

  129. Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anticytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation. A meta-analysis. Bone Marrow Transplant. 1994;13:163–7.

    PubMed  CAS  Google Scholar 

  130. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant. A critical review. Bone Marrow Transplant. 1994;13:499–510.

    PubMed  CAS  Google Scholar 

  131. Sullivan KM, Kopecky KJ, Jocum J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–12.

    Article  PubMed  CAS  Google Scholar 

  132. Wolff SN, Fay JW, Herzig RH, et al. High-dose intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med. 1993;118:937–42.

    PubMed  CAS  Google Scholar 

  133. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients. a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–10.

    Article  PubMed  CAS  Google Scholar 

  134. Tomblyn M, Chiller T, Einsele E, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2009;15:1143–238.

    Article  PubMed  CAS  Google Scholar 

  135. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70–5.

    Article  PubMed  CAS  Google Scholar 

  136. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet. 1994;343:749–53.

    Article  PubMed  CAS  Google Scholar 

  137. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med. 1991;325:1601–7.

    Article  PubMed  CAS  Google Scholar 

  138. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.

    PubMed  CAS  Google Scholar 

  139. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med. 1993;118:179–84.

    PubMed  CAS  Google Scholar 

  140. Salzberger B, Bowden RA, Hackman RC, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease. Risk factors and outcome. Blood. 1997;90:2502–8.

    PubMed  CAS  Google Scholar 

  141. Stocchi R, Szydlo R, Craddock C, et al. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant. 1999;23:705–9.

    Article  PubMed  CAS  Google Scholar 

  142. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis. 1994;19:287–98.

    Article  PubMed  CAS  Google Scholar 

  143. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation. Where do we stand? Blood. 1994;83:2392–8.

    PubMed  CAS  Google Scholar 

  144. Devine SM, Wingard JR. Viral infections in severely immunocompromised cancer patients. Support Care Cancer. 1994;2: 355–68.

    Article  PubMed  CAS  Google Scholar 

  145. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients. Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–58.

    Article  PubMed  Google Scholar 

  146. Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp 65 antigenemia. J Infect Dis. 1998;178:1153–7.

    Article  PubMed  CAS  Google Scholar 

  147. Przepiorka D, Ippoliti C, Panina A, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994;13:461–4.

    PubMed  CAS  Google Scholar 

  148. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cytomegalovirus after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:777–81.

    PubMed  CAS  Google Scholar 

  149. Zaia JA, Gallez-Hawkins GM, Klongmate J, et al. Late bacterial and fungal sepsis and mortality after BMT are increased by duration of early ganciclovir preemptive therapy for CMV infection. Blood. 1998;92 Suppl 1:518a (abstract no. 2128).

    Google Scholar 

  150. Polis MA, Masur H. Promising new treatments for cytomegalovirus retinitis. JAMA. 1995;273:1457–9.

    Article  PubMed  CAS  Google Scholar 

  151. Drew WL, Stempien MJ, Andrews J, et al. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis. 1999;179: 1352–5.

    Article  PubMed  CAS  Google Scholar 

  152. Drew WL. Ganciclovir resistance. A matter of time and titre. Lancet. 2000;356:609–10.

    Article  PubMed  CAS  Google Scholar 

  153. Brown F, Banken L, Saywell K. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167–76.

    Article  PubMed  CAS  Google Scholar 

  154. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV and CMV-seropositive subjects. J Clin Pharmacol. 1999;39:800–4.

    Article  PubMed  CAS  Google Scholar 

  155. Pescovits MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811–5.

    Article  Google Scholar 

  156. Palladino M, Laurenti L, Chiusolo P, et al. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. Acta Haematol. 2010;123(4):230–4.

    Article  PubMed  CAS  Google Scholar 

  157. van der Heiden PL, Kalpoe JS, et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 2006;37: 693–8.

    Article  PubMed  CAS  Google Scholar 

  158. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(9):851–6.

    Article  PubMed  CAS  Google Scholar 

  159. Liu W, Baruch D, Kuppermann BD, et al. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. J Infect Dis. 1998;177:1176–81.

    Article  PubMed  CAS  Google Scholar 

  160. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol. 1996;70:1390–5.

    PubMed  CAS  Google Scholar 

  161. Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997;176:69–77.

    Article  PubMed  CAS  Google Scholar 

  162. Erice A, Gil-Roda C, Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 1997;175:1087–92.

    Article  PubMed  CAS  Google Scholar 

  163. Perez JL. Resistance to antivirals in human cytomegalovirus. Mechanisms and clinical significance. Microbiologia. 1997;13: 343–52.

    PubMed  CAS  Google Scholar 

  164. Nichols WG, Corey L, Gooley T, et al. Rising pp 65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation. risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–74.

    Article  PubMed  CAS  Google Scholar 

  165. Aschan J, Ringden O, Ljungman P, Lonnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis. 1992;24:143–50.

    Article  PubMed  CAS  Google Scholar 

  166. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I–II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J infect Dis JID. 1992;166:473–9.

    Article  CAS  Google Scholar 

  167. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant. 1994;13:783–8.

    PubMed  CAS  Google Scholar 

  168. Moretti S, Zikos P, Van Lint MT, et al. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT). A randomised study. Bone Marrow Transplant. 1998;22:175–80.

    Article  PubMed  CAS  Google Scholar 

  169. Ordemann R, Naumann R, Geissler G, et al. Foscarnet—an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation. Ann Hematol. 2000;79:432–6.

    Article  PubMed  CAS  Google Scholar 

  170. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet–ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. 1995;62:376–80.

    Article  Google Scholar 

  171. Razis E, Cook P, Mittelman A, Ahmed T. Treatment of ganciclovir resistant cytomegalovirus with foscarnet. A report of two cases occurring after bone marrow transplantation. Leuk Lymphoma. 1994;12:477–80.

    Article  PubMed  CAS  Google Scholar 

  172. Lalezari JP, Holland GN, Kramer F, et al. Randomized controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr. 1998;17:339–44.

    Article  CAS  Google Scholar 

  173. Jabs DA, Freeman WR, Jacobson M, The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis. The HPMPC Peripheral Cytomegalovirus Retinitis Trial. AIDS. 2000;14:1571–81.

    Article  Google Scholar 

  174. Plosker GL, Noble S. Cidofovir. A review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs. 1999;58:325–45.

    Article  PubMed  CAS  Google Scholar 

  175. Ljungman P, Deliliers GL, Ribaud P, et al. Cidofovir for treatment of CMV and adenovirus infections in allogeneic stem cell ­transplant recipients. Blood. 1999;94 Suppl 1:396a (abstract no. 1753).

    Google Scholar 

  176. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999;28:618–23.

    Article  PubMed  CAS  Google Scholar 

  177. Atkinson K, Nivison-Smith I, Dodds A, et al. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant. 1998;21:691–5.

    Article  PubMed  CAS  Google Scholar 

  178. Zaia JA, Gallez-Hawkins GM, Teftmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997;176:782–5.

    Article  PubMed  CAS  Google Scholar 

  179. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Hematol. 1993;83: 118–24.

    Article  CAS  Google Scholar 

  180. Machado CM, Dulley FL, Vilas-Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or preemptive ganciclovir therapy. Bone Marrow Transplant. 2000;26:413–7.

    Article  PubMed  CAS  Google Scholar 

  181. Boeckh M, Riddell SR, Cunningham T, et al. Increased risk of late CMV infection and disease in allogeneic marrow transplant ­recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. Blood. 1996;86 Suppl 1:302a (abstract no. 1195).

    Google Scholar 

  182. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757–63.

    Article  PubMed  CAS  Google Scholar 

  183. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific Tcell responses after allogeneic bone marrow transplant. Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–9.

    PubMed  CAS  Google Scholar 

  184. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants. importance of viral load and T-cell immunity. Blood. 2003;101:407–14.

    Article  PubMed  CAS  Google Scholar 

  185. Zaia JA, Gallez-Hawkins G, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997;176:782–5.

    Article  PubMed  CAS  Google Scholar 

  186. Riddell SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 1994;14:S78–84.

    PubMed  Google Scholar 

  187. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science. 1992;257:238.

    Article  PubMed  CAS  Google Scholar 

  188. Riddell SR, Reusser P, Greenberg PD. Cytotoxic T-cells specific for cytomegalovirus. A potential therapy for immunocompromised hosts. Rev Infect Dis. 1991;13 Suppl 1:966–73.

    Article  Google Scholar 

  189. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother. 2000;45(Suppl T3):35–43.

    Article  PubMed  CAS  Google Scholar 

  190. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991;163:716–9.

    Article  PubMed  CAS  Google Scholar 

  191. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med. 1994;120:143–58.

    PubMed  CAS  Google Scholar 

  192. Schleiss MR. Cytomegalovirus vaccines and methods of production (WO20009049138). the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface. Expert Opin Ther Pat. 2010;20:597–602.

    Article  PubMed  CAS  Google Scholar 

  193. Goffinet DR, Glatstein EJ, Merigan TC. Herpes zoster-varicella infections and lymphoma. Ann Intern Med. 1972;76:235.

    PubMed  CAS  Google Scholar 

  194. Coker DD, Morris DM, Coleman JJ, et al. Infection among 210 patients with surgically staged Hodgkin’s disease. Am J Med. 1993;75:97.

    Article  Google Scholar 

  195. Atkinson K, Meyers JD, Storb R, Prentice RL, Thomas ED. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation. 1980;29:47.

    Article  PubMed  CAS  Google Scholar 

  196. Locksley PRM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172–81.

    Article  PubMed  CAS  Google Scholar 

  197. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989;74:1424–7.

    PubMed  CAS  Google Scholar 

  198. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation. Incidence, risk factors and complications. Bone Marrow Transplant. 1994;13:277–83.

    PubMed  CAS  Google Scholar 

  199. Feldman S, Lott L. Varicella in children with cancer. Impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80:46.

    Google Scholar 

  200. Schiller GJ, Nimer SD, Gajewski JL, Golde D. Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1991;7:489–91.

    PubMed  CAS  Google Scholar 

  201. Yagi T, Karasuno T, Hasegawa T. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation. Importance of empiric therapy with acyclovir. Bone Marrow Transplant. 2000;25:1003–5.

    Article  PubMed  CAS  Google Scholar 

  202. David DS, Teftmeier BR, O’Donnell MR, et al. Visceral varicellazoster after bone marrow transplantation. Report of a case series and review of the literature. Am J Gastroenterol. 1998;93:810–3.

    Article  PubMed  CAS  Google Scholar 

  203. Ljungman P, Lönnqvist B, Gahrton G, Ringdén O, Sundqvist V-A, Wahren B. Clinical and subclinical reactivations of varicellazoster virus in immunocompromised patients. J Infect Dis. 1986;153: 840–7.

    Article  PubMed  CAS  Google Scholar 

  204. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.

    Article  PubMed  CAS  Google Scholar 

  205. Schmidt NJ, Ballo D, Devlin V, Woodie JD, Emmons RW. Direct immuno-fluorescence staining for detection of herpes simplex and varicella-zoster virus antigens in vesicular lesion and certain tissue specimens. J Clin Microbiol. 1980;12:651–5.

    PubMed  CAS  Google Scholar 

  206. Balfour Jr HH, Bean B, Laskin OL, Burroughs Wellcome Collaborative Acyclovir Study Group, et al. cyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448–53.

    Article  PubMed  Google Scholar 

  207. Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation. 1984;37:571.

    Article  PubMed  CAS  Google Scholar 

  208. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicellazoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986;314:208–12.

    Article  PubMed  CAS  Google Scholar 

  209. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J. 1986;293:1529–32.

    Article  CAS  Google Scholar 

  210. Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G, for the Nordic Bone Marrow Transplant Group. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant. 1989;4:613–5.

    PubMed  CAS  Google Scholar 

  211. Whitley RJ, Soong S-J, Dolin R, NIAID Collaborative Antiviral Study Group, et al. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Eng J Med. 1982;307:971.

    Article  CAS  Google Scholar 

  212. Merigan TC, Rand KH, Pollard RB, et al. Human leukocyte interferon for the treatment of herpes-zoster in patients with cancer. N Engl J Med. 1978;298:981.

    Article  PubMed  CAS  Google Scholar 

  213. Winston DJ, Eron LJ, Ho M, et al. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med. 1988;85:147.

    Article  PubMed  CAS  Google Scholar 

  214. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster immunocompetent adults. Antimicrob Agents Chemother. 1995;39: 1546–53.

    Article  PubMed  CAS  Google Scholar 

  215. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster. Effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89–96.

    PubMed  CAS  Google Scholar 

  216. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster. Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9:863–9.

    Article  PubMed  CAS  Google Scholar 

  217. Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect. 2001;34:138–42.

    PubMed  CAS  Google Scholar 

  218. Arora A, Mendoza N, Brantley J, et al. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis. 2008;197:1289–95.

    Article  PubMed  CAS  Google Scholar 

  219. Boivin G, Edleman CK, Pedneault L, Talarico CL, Biron KK, Balfour Jr HH. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994;170:68–75.

    Article  PubMed  CAS  Google Scholar 

  220. Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991;115:19–21.

    PubMed  CAS  Google Scholar 

  221. Gershon AA. Live attenuated varicella vaccine. Perspective. J Infect Dis. 1985;152:859.

    Article  PubMed  CAS  Google Scholar 

  222. Gershon AA. Live attenuated varicella vaccine. J Pediatr. 1987;110:154.

    Article  PubMed  CAS  Google Scholar 

  223. Gershon AA, Steinberg SP, Varicella Vaccine Collaborative Study Group of the NIAID. Persistence of immunity of varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989;320:892.

    Article  PubMed  CAS  Google Scholar 

  224. Gershon AA, Steinberg SP, National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine. Protection in healthy adults compared with leukemic children. J Infect Dis. 1990;161:661.

    Article  PubMed  CAS  Google Scholar 

  225. Lawrence R, Gershon AA, Holzman R, et al. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988;318:543.

    Article  PubMed  CAS  Google Scholar 

  226. Diaz PS, Au D, Smith S, et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics. 1991;87:166–70.

    PubMed  CAS  Google Scholar 

  227. Weinstock DM, Boeckh M, Sepkowitz KA. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:1096–7.

    Article  PubMed  Google Scholar 

  228. Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes. 2006;13:60–5.

    PubMed  Google Scholar 

  229. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant. 1986;1:185–92.

    PubMed  CAS  Google Scholar 

  230. Perren TJ, Powles RL, Easton D, et al. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med. 1988;85:99–101.

    PubMed  CAS  Google Scholar 

  231. Sempere A, Sanz GF, Senent L, et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant. 1992;10:495–8.

    PubMed  CAS  Google Scholar 

  232. Steer CB, Szer J, Sasadeusz J, et al. Varicella-zoster infection after allogeneic bone marrow transplantation. Incidence, risk factors and prevention with low-dose acyclovir and ganciclovir. Bone Marrow Transplant. 2000;25:657–64.

    Article  PubMed  CAS  Google Scholar 

  233. Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer. 1989;59:434–8.

    Article  PubMed  CAS  Google Scholar 

  234. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation. no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110: 3071–7.

    Article  PubMed  CAS  Google Scholar 

  235. Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, Tsuji K, Takahashi M. Studies on transfer of varicella-zoster virus specific T-cell immunity from bone marrow donor to recipient. Blood. 1990;75:806–9.

    PubMed  CAS  Google Scholar 

  236. Hoagland RJ. The transmission of infectious mononucleosis. Am J Med Sci. 1955;229:262–72.

    Article  PubMed  CAS  Google Scholar 

  237. Nilsson K, Klein G, Henle W, Henle G. The establishment of lymphoblastoid cell lines from adult and from foetal human lymphoid tissue and its dependence on EBV. Int J Cancer. 1971;8:443–50.

    PubMed  CAS  Google Scholar 

  238. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225–30.

    Article  PubMed  CAS  Google Scholar 

  239. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections. Biology, pathogenesis and management. Ann Intern Med. 1993;118:45–8.

    PubMed  CAS  Google Scholar 

  240. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Ann Rev Med. 1987;38:195–209.

    Article  PubMed  CAS  Google Scholar 

  241. Barbera JA, Hayashi S, Hegele RG, et al. Detection of Epstein-Barr virus in lymphocytic interstitial pneumonia by in situ hybridization. Am Rev Respir Dis. 1992;145:940–6.

    PubMed  CAS  Google Scholar 

  242. Bird AG, Britton S. The relationship between Epstein-Barr virus and lymphoma. Semin Hematol. 1982;19:285.

    PubMed  CAS  Google Scholar 

  243. Hanto DW, Frizzera G, Gajl-Peczxalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306:913.

    Article  PubMed  CAS  Google Scholar 

  244. Syndman DR, Rudders RA, Daoust P, et al. Infectious mononucleosis in an adult progressing to fatal immunoblastic lymphoma. Ann Intern Med. 1982;96:737.

    Google Scholar 

  245. Purtilo DT, Sakamoto K, Barnabei V, XLP Collaborators, et al. Epstein-Barr virus-induced diseases in boys and the X-linked lymphoproliferative syndrome (XLP). Am J Med. 1982;73:49.

    Article  PubMed  CAS  Google Scholar 

  246. Henle W, Henle G, Horwitz CA. Epstein-Barr virus-specific diagnostic tests in infectious mononucleosis. Hum Pathol. 1974;5:551–65.

    Article  PubMed  CAS  Google Scholar 

  247. Tosato G, Macrath I, Koski I, Dooley N, Blaese M. Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med. 1979;301:1133–7.

    Article  PubMed  CAS  Google Scholar 

  248. Moss DJ, Wallace LE, Rickinson AB, Epstein MA. Cytotoxic T cell recognition of Epstein-Barr-virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated. Eur J Immunol. 1981;11:686–93.

    Article  PubMed  CAS  Google Scholar 

  249. Sumaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings. Pediatrics. 1985;75:1003–10.

    PubMed  CAS  Google Scholar 

  250. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. Blood. 1995;85:552–65.

    PubMed  CAS  Google Scholar 

  251. Ballerini P, Gaidano G, Inghirami G, Gong JZ, Saglio G, Knowles DM, Dalla-Favera R. Multiple genetic alterations in AIDS-associated lymphomas. Blood. 1991;78:327a.

    Google Scholar 

  252. Chang RS, Lewis JP, Abildgaard CF. Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population. N Engl J Med. 1973;289:1325–9.

    Article  PubMed  CAS  Google Scholar 

  253. Ambinder RF, Wingard JR, Burns WH, Hayward SD, Saral S, Perry HR, Santos GW, Hayward GS. Detection of Epstein-Barr virus DNA in mouthwashes by hybridization. J Clin Microbiol. 1985;21:353–6.

    PubMed  CAS  Google Scholar 

  254. Lin JC, Lin SC, De BK, Chan WC, Evatt BL, Chan WC. Precision of genotyping for Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3 C, and EBER). Predominance of type A virus associated with Hodgkin’s disease. Blood. 1993;81:3372–81.

    PubMed  CAS  Google Scholar 

  255. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988;5:719–27.

    Article  Google Scholar 

  256. Ho M, Miller G, Atchison RW, Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions. The role of primary infection. J Infect Dis. 1985;152:876–86.

    Article  PubMed  CAS  Google Scholar 

  257. Chang RS, Lewis JP, Reynolds RD, et al. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Intern Med. 1974;88:34–40.

    Google Scholar 

  258. Strauch B, Siegel N, Andrews LL, et al. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet. 1974; 1:234.

    Article  PubMed  CAS  Google Scholar 

  259. Cheeseman SH, Henle W, Rubin RH. Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med. 1980;93:39–42.

    PubMed  CAS  Google Scholar 

  260. Strauch B, Andrews L-L, Siegel N, Miller G. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet. 1975;1:234–7.

    Google Scholar 

  261. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res. 1981;41:4222–5.

    PubMed  CAS  Google Scholar 

  262. Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. N Engl J Med. 1985;313:1564–71.

    Article  PubMed  CAS  Google Scholar 

  263. Reichart PA, Langford A, Gelderblom HR, Pohle H-D, Becker J, Wolf H. Oral hairy leukoplakia. Observations in 95 cases and review of the literature. J Oral Pathol Med. 1989;18:410–5.

    Article  PubMed  CAS  Google Scholar 

  264. Laine SS, Happonen R-P, Niemelä M. Oral hairy leukoplakia is not a specific sign of HIV-infection but related to immunosuppression in general. J Oral Pathol Med. 1989;18:28–31.

    Article  PubMed  Google Scholar 

  265. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg. 1983;198:356–69.

    Article  PubMed  CAS  Google Scholar 

  266. Hanto DW, Sakamoto K, Purtilo D, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery. 1981;90:204–13.

    PubMed  CAS  Google Scholar 

  267. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 1991;70:137.

    Article  CAS  Google Scholar 

  268. Lange B, Henle W, Meyers JD, et al. Epstein-Barr virus-related serology in marrow transplant recipients. Int J Cancer. 1980;26:151–7.

    Article  PubMed  CAS  Google Scholar 

  269. Wingard JR, Lin SC, Mar EC, Devine SM, Pascuzzi CC, Dix SP, Saral R, Lin JC. Epstein-Barr Virus (EBV) infection in bone marrow transplant (BMT) patients. J Cell Biochem. 1994;18:62 (abstract no. G116).

    Google Scholar 

  270. Shearer WT, Ritz J, Finegold MJ. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med. 1985;312:1151–9.

    Article  PubMed  CAS  Google Scholar 

  271. Martin PJ, Shulman HM, Schubach WH. Fatal Epstein-Barrvirus-associated proliferation of donor B cells after treatment of acute-graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med. 1984;101:310–5.

    PubMed  CAS  Google Scholar 

  272. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520–9.

    PubMed  CAS  Google Scholar 

  273. D’Amore ESG, Manivel JC, Gajl-Peczalska KJ, Litz CE, Copenhaver CM, Shapiro RS, Strickler JG. B-Cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on Epstein-Barr virus detection in-situ hybridization. Cancer. 1991;68:1285–95.

    Article  PubMed  Google Scholar 

  274. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321:784–9.

    Article  PubMed  CAS  Google Scholar 

  275. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–43.

    PubMed  CAS  Google Scholar 

  276. Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett. 1996;52:145–52.

    Article  PubMed  CAS  Google Scholar 

  277. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant. 1996;18:377–82.

    PubMed  CAS  Google Scholar 

  278. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation. A multi-institutional study. Blood. 1999;94:2208–16.

    PubMed  CAS  Google Scholar 

  279. Lazzarino M, Orlandi E, Baldanti F, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 1999;107:877–82.

    Article  PubMed  CAS  Google Scholar 

  280. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [(9-2-hydroxyethoxymethyl]guanine) on Epstein-Barr virus DNA replication. J Virol. 1980;34:560–8.

    PubMed  CAS  Google Scholar 

  281. Anderson J, Britton S, Ernberg I, Andersson U, Henle W, Sköldenberg B, Tisell Å. Effect of acyclovir on infectious mononucleosis. A double-blind, placebo-controlled study. J Infect Dis. 1986;153:282–90.

    Google Scholar 

  282. Pagano JS, Sixbey JW, Lin J-C. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother. 1983;12:113–21.

    PubMed  Google Scholar 

  283. Andersson J, Sköldenberg B, Henle W, et al. Acyclovir treatment in infectious mononucleosis. A clinical and virological study. Infection. 1987;15:S14–21.

    Article  PubMed  Google Scholar 

  284. Resnick L, Herbst JS, Ablashi D, Atherton S, Frank B, Rosen L, Horwitz SN. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA. 1988;259:384–8.

    Article  PubMed  CAS  Google Scholar 

  285. Newman C, Polk BF. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihyroxy-2-propoxymethyl) guanine (DHPG). Ann Intern Med. 1987;107:348–50.

    PubMed  CAS  Google Scholar 

  286. Pirsch JD, Stratta RJ, Sollinger HW, Hafez GR, D’Alessandro AM, Kalayoglu M, Belzer FO. Treatment of severe Epstein-Barr virus induced lymphoproliferative syndrome with ganciclovir. Two cases after solid organ transplantation. Am J Med. 1989;86:241–4.

    Article  PubMed  CAS  Google Scholar 

  287. Ishida Y, Kokota Y, Tauchi H, Fukuda M, Takaoka T, Hayashi M, Matsuda H. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet. 1993;341:560–1.

    Article  PubMed  CAS  Google Scholar 

  288. Andersson JP, Andersson UG, Ernberg IT, Britton SF, DeLey M. Effects of pure interferons on Epstein-Barr virus infection in vitro. J Virol. 1985;54:615–8.

    PubMed  CAS  Google Scholar 

  289. Lidin B, Lamon EW. Antiviral effects of interferon on a somatic cell hybrid between two Burkitt’s lymphoma cell lines of different interferon sensitivities. Infect Immun. 1982;36:847–9.

    PubMed  CAS  Google Scholar 

  290. Lin J-C, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxyethyl)guanine against replication of Epstein-Barr virus. J Virol. 1984;50:50–5.

    PubMed  CAS  Google Scholar 

  291. Moore MD, Cannon MJ, Sewall A, Finlayson M, Okimoto M, Nemerow GR. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats. J Virol. 1991;65:3559–65.

    PubMed  CAS  Google Scholar 

  292. Savoie A, Perpête C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 1994;83:2715–22.

    PubMed  CAS  Google Scholar 

  293. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654–61.

    PubMed  CAS  Google Scholar 

  294. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease. Prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–14.

    PubMed  CAS  Google Scholar 

  295. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972–8.

    Article  PubMed  Google Scholar 

  296. Niedermeyer J, Hoffmeyer F, Hertenstein B, et al. Treatment of lymphoproliferative disease with Rituximab. Lancet. 2000; 355:499.

    Article  PubMed  CAS  Google Scholar 

  297. Kuehnke I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (Rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Blood. 2000;95:1502–5.

    Google Scholar 

  298. McGuirk JP, Seropian S, Howe G, et al. Use of Rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant. 1999;24:1253–8.

    Article  PubMed  CAS  Google Scholar 

  299. Meerbach A, Wutzler P, Hafer R, et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol. 2008;80:441–54.

    Article  PubMed  CAS  Google Scholar 

  300. Papadopopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.

    Article  Google Scholar 

  301. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–55.

    PubMed  CAS  Google Scholar 

  302. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157: 217–22.

    Article  PubMed  CAS  Google Scholar 

  303. Lucas KG, Sun Q, Burton RL, et al. A phase I–II trial to examine the toxicity of CMVand EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther. 2000;11:1453–63.

    Article  PubMed  CAS  Google Scholar 

  304. Heslop HE, Perez M, Benaim E, et al. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999;14:154–6.

    Article  PubMed  CAS  Google Scholar 

  305. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes. Nat Med. 1996;2:551–5.

    Article  PubMed  CAS  Google Scholar 

  306. Pellett PE, Black JB, Yamamoto M. Human herpesvirus 6. The virus and the search for its role as a human pathogen. Adv Virus Res. 1992;41:1–52.

    Article  PubMed  CAS  Google Scholar 

  307. Leach CT. Human herpesvirus-6 and -7 infections in children. Agents of roseola and other syndromes. Curr Opin Pediatr. 2000;12:269–74.

    Article  PubMed  CAS  Google Scholar 

  308. Torelli G, Marasca R, Luppi M, et al. Human herpesvirus-6 in human lymphomas. Identification of specific sequences in Hodgkin’s lymphomas by polymerase chain reaction. Blood. 1991;77:2251–8.

    PubMed  CAS  Google Scholar 

  309. Yin SY, Ming HA, Jahan N, Manak M, Jaffe ES, Levine PH. In situ hybridization detection of human herpesvirus 6 in biopsy specimens from Chinese patients with non-Hodgkin’s lymphoma. Arch Pathol Lab Med. 1993;117:502–6.

    PubMed  CAS  Google Scholar 

  310. Di Luca D, Dolcetti R, Mirandola P, et al. Human herpesvirus 6. A survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis. 1994;170:211–5.

    Article  PubMed  Google Scholar 

  311. Kurata T, Iwasaki T, Sata T, et al. Viral pathology of human herpesvirus 6 infection. Adv Exp Med Biol. 1990;278:39.

    Article  PubMed  CAS  Google Scholar 

  312. Yoshikawa T, Suga S, Asano Y, et al. Human herpesvirus 6 ­infection in bone marrow transplantation. Blood. 1991;78:1381.

    PubMed  CAS  Google Scholar 

  313. Asano Y, Yoshikawa T, Suga S, et al. Reactivation of herpesvirus type 6 in children receiving bone marrow transplants for leukemia. N Engl J Med. 1991;324:634.

    PubMed  CAS  Google Scholar 

  314. Wilborn F, Brinkmann V, Schmidt CA, Neipel F, et al. Herpesvirus type 6 in patients undergoing bone marrow transplantation. Serologic features and detection by polymerase chain reaction. Blood. 1994;83:3052.

    PubMed  CAS  Google Scholar 

  315. Takemoto Y, Takatsuka H, Wada H, et al. Evaluation of CMV/human herpes virus-6 positivity in bronchoalveolar lavage fluids as early detection of acute GVHD following BMT. Evidence of a significant relationship. Bone Marrow Transplant. 2000;26:77–81.

    Article  PubMed  CAS  Google Scholar 

  316. Drobyski WR, Dunne WM, Burd EM. Human herpesvirus 6 (HHV-6) infection in allogeneic bone marrow transplant recipients. I. Evidence for a marrow suppressive role for HHV-6 in vivo. J Infect Dis. 1993;167:735.

    Article  PubMed  CAS  Google Scholar 

  317. Knox KK, Carrigan DR. In vitro suppression of bone marrow ­progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis. 1992;165:925.

    Article  PubMed  CAS  Google Scholar 

  318. Carrigan DR, Knox KK. Human herpesvirus 6 (HHV-6) isolation from bone marrow. HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood. 1994;84:3307–10.

    PubMed  CAS  Google Scholar 

  319. Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, Ash RC. Interstitial pneumonitis associated with human herpesvirus six (HHV-6) infection in marrow transplant patients. Lancet. 1991;338:147.

    Article  PubMed  CAS  Google Scholar 

  320. Cone RW, Hackman RC, Huang MW, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med. 1993;329:156.

    Article  PubMed  CAS  Google Scholar 

  321. Drobyski WR, Knox KK, Majewski D, Carrigan DR. Fatal encephalitis due to variant B human herpesvirus 6 infection in a bone marrow transplant recipient. N Engl J Med. 1994;330:1356.

    Article  PubMed  CAS  Google Scholar 

  322. Wang F-Z, Linde A, Dahl H, et al. Human herpesvirus 6 infection inhibits specific lymphocyte proliferation responses and is related to lymphocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 1999;24:1201–6.

    Article  PubMed  CAS  Google Scholar 

  323. Griffiths PB, Emory VO, Loe C, Johnson MA, McLaughlin J. HHV-6 in AIDS. Lancet. 1994;343:1104–5.

    Article  PubMed  CAS  Google Scholar 

  324. Knox KK, Carrigan DR. HHV-6 and CMV pneumonitis in immunocompromised patients. Lancet. 1994;343:1647.

    Article  PubMed  CAS  Google Scholar 

  325. Lusso P, Gallo RC. HHV-6 and CMV pneumonitis in immunocompromised patients. Lancet. 1994;343:1647–8.

    Article  PubMed  CAS  Google Scholar 

  326. Burns WH, Sandford GR. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis. 1990;162:634–7.

    Article  PubMed  CAS  Google Scholar 

  327. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–40.

    Article  PubMed  Google Scholar 

  328. Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohono K, Kashima K, Ohtsuka E, Kadota J. Human herpes virus 6 DNA in plasma after allogeneic stem cell transplantation. incidence and clinical significance. J Infect Dis. 2006;193:68–79.

    Article  PubMed  CAS  Google Scholar 

  329. Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:563–6.

    Article  PubMed  CAS  Google Scholar 

  330. Visser AM, van Doorman GJ, Cornelissen JJ, van den Bent MJ. Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplant. Eur Neurol. 2005;54:233–4.

    Article  PubMed  CAS  Google Scholar 

  331. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1031–7.

    Article  PubMed  Google Scholar 

  332. Hentrich M, Oruzio D, Jager G, Schemmer M, Schleuning M, Schiel X, Hiddemann W, Kolb HJ. Impact of human herpesvirus-6 after hematopoietic stem cell transplantation. Br J Haematol. 2005;128:66–72.

    Article  PubMed  Google Scholar 

  333. Pohlmann C, Shetelig J, Reuner U, Bornhauser M, Illmer T, Kiani A, Ehninger G, Jacobs E, Rohayem J. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis. 2007;44:e118–20.

    Article  PubMed  Google Scholar 

  334. Ogata M, Satou T, Kawano R, Goto K, Ikewaki J, Kohno K, Ando T, Miyazaki Y, Ohtsuka E, Saburi Y, Saikawa T, Kadota JI. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantion. a prospective evaluation. Bone Marrow Transplant. 2008;41:279–85.

    Article  PubMed  CAS  Google Scholar 

  335. Boutolleau D, Fernandez C, Andre E, Imbert-Marcille BM, Milpied N, Agut H, Gautheret-Dejean A. Human herpesvirus (HHV)-6 and HHV-7. two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 2003;187:179–86.

    Article  PubMed  Google Scholar 

  336. Ward KN, White RP, Mackinnon S, Hanna M. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant. 2002;30:983–5.

    Article  PubMed  CAS  Google Scholar 

  337. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.

    Article  PubMed  CAS  Google Scholar 

  338. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and those without HIV infection. N Engl J Med. 1995;332:1181–5.

    Article  PubMed  CAS  Google Scholar 

  339. Huang YQ, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi’s sarcoma. Lancet. 1995;345:759–61.

    Article  PubMed  CAS  Google Scholar 

  340. Knowles DM, Cesarman E. The Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Kaposi’s sarcoma, malignant lymphoma, and other diseases. Ann Oncol. 1997;8:S123–9.

    Article  Google Scholar 

  341. Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in IDS-related body-cavity-based lymphoma. N Engl J Med. 1995;332:1186–91.

    Article  PubMed  CAS  Google Scholar 

  342. Schulte KM, Talat N. Castleman’s disease-a two compartment model of HHV8 infection. Nat Rev Clin Oncol. 2010;7(9):533–43.

    Article  PubMed  CAS  Google Scholar 

  343. Rettig NB, Ma HJ, Vescio RA, et al. Kaposi’s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1997;276:1851–4.

    Article  PubMed  CAS  Google Scholar 

  344. Pan L, Milligan L, Michaeli J, et al. Polymerase chain reaction detection of Kaposi’s sarcoma-associated herpesvirus-optimized protocols and their application to myeloma. J Mol Diagn. 2001;3:32–8.

    Article  PubMed  CAS  Google Scholar 

  345. Tedeschi R, Kvarnung M, Knekt P, et al. A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Br J Cancer. 2001;84(1):122–5.

    Article  PubMed  CAS  Google Scholar 

  346. Townsend TR, Bolyard EA, Yolken RH, et al. Outbreak of coxsackie A1 gastroenteritis. A complication of bone marrow transplantation. Lancet. 1982;1:820–3.

    Article  PubMed  CAS  Google Scholar 

  347. Aquino VM, Farah RA, Lee MC, et al. Disseminated coxsackie A9 infection complicating bone marrow transplantation. Pediatr Infect Dis J. 1996;15:1053–4.

    Article  PubMed  CAS  Google Scholar 

  348. Galama JM, de Leeuw N, Wittebol S, et al. Prolonged enteroviral infection in a patient who developed pericarditis and heart failure after bone marrow transplantation. Clin Infect Dis. 1996;22:1004–8.

    Article  PubMed  CAS  Google Scholar 

  349. Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med. 1982;306:1009–112.

    Article  Google Scholar 

  350. Troussard X, Bauduer F, Gallet E, et al. Virus recovery from stools of patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1993;12:573–6.

    PubMed  CAS  Google Scholar 

  351. Ambinder RF, Burns W, Forman M, et al. Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Intern Med. 1986;146:1400–1.

    Article  PubMed  CAS  Google Scholar 

  352. Miyamura K, Taketama K, Kojima S, et al. Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4:533–5.

    PubMed  CAS  Google Scholar 

  353. Londergan TA, Walzak MP. Hemorrhagic cystitis due to adenovirus infection following bone marrow transplantation. J Urol. 1994;151:1013–4.

    PubMed  CAS  Google Scholar 

  354. Schmitz H, Wigand R, Heinrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol. 1983;117:455–66.

    PubMed  CAS  Google Scholar 

  355. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infections after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;23:277–82.

    Article  PubMed  CAS  Google Scholar 

  356. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998;27:1194–2000.

    Article  PubMed  CAS  Google Scholar 

  357. Shields AF, Hackman RC, Fife KH, et al. Adenovirus infection in patients undergoing bone-marrow transplantation. N Engl J Med. 1985;312:529–33.

    Article  PubMed  CAS  Google Scholar 

  358. Flomenberg P, Babbitt J, Drobyski WR, Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775–81.

    Article  PubMed  CAS  Google Scholar 

  359. Howard DS, Phillips GL, Reece DE, Munn RK, Henslee-Downey J, Pittard M, Barker M, Pomeroy C. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29:1494–501.

    Article  PubMed  CAS  Google Scholar 

  360. Zahradnik JM, Spencer MJ, Porter DD. Adenovirus infection in the immunocompromised patient. Am J Med. 1980;68:725.

    Article  PubMed  CAS  Google Scholar 

  361. Carmichael Jr GP, Zahradnik JM, Moyer GH, Porter DD. Adenovirus hepatitis in an immunosuppressed adult patient. Am J Clin Pathol. 1979;71:352.

    PubMed  Google Scholar 

  362. Somervaille TCP, Kirk S, Dogan A, Landon GV, Mackinnon S. Fulminant hepatic failure caused by adenovirus infection following bone marrow transplantation for Hodgkin’s disease. Bone Marrow Transplant. 2000;24:99–101.

    Article  Google Scholar 

  363. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation. Failure of intravenous ribavirin therapy. Bone Marrow Transplant. 1999;23:1209–11.

    Article  PubMed  CAS  Google Scholar 

  364. Childs R, Sanchez C, Engler H, Preuss J, Rosenfeld S, Dunbar C, van Rhee F, Plante M, Phang S, Barrett AJ. High incidence of adenoand polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant. 1998;22:889–93.

    Article  PubMed  CAS  Google Scholar 

  365. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503–9.

    Article  PubMed  Google Scholar 

  366. Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:677–86.

    Article  PubMed  CAS  Google Scholar 

  367. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation. incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–27.

    Article  PubMed  CAS  Google Scholar 

  368. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol. 2005;130:595–603.

    Article  PubMed  CAS  Google Scholar 

  369. van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in paediatric stem cell transplant recipients. increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36:39–50.

    Article  PubMed  Google Scholar 

  370. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reducedintensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;10:186–94.

    Article  PubMed  Google Scholar 

  371. Chen FE, Liang RHS, Lo JY, Yuen KY, Chan TK, Peiris M. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997;20:997–9.

    Article  PubMed  CAS  Google Scholar 

  372. Wreghitt TG, Gray JJ, Ward KN, Salt A, Taylor DL, Alp NJ, Tyms AS. Disseminated adenovirus infection after liver transplantation and its possible treatment with ganciclovir. J Infect. 1989;19:88–9.

    Article  PubMed  CAS  Google Scholar 

  373. Duggan JM, Farrehi J, Duderstadt S, Turner NJ, Fekety R. Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient. Am J Med. 1997;103:439–40.

    Article  PubMed  CAS  Google Scholar 

  374. Shetty AK, Gans HA, So S, Millan MT, Arvin AM, Gutierrez KM. Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonol. 2000;29:69–73.

    Article  PubMed  CAS  Google Scholar 

  375. Miyamura K, Hamaguchi M, Taji H, Kanie T, Kohno A. Successful ribavirin therapy for severe adenovirus hemorhhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant. 2000;25:545–80.

    Article  PubMed  CAS  Google Scholar 

  376. Jurado CM, Hernandez MF, Navarro JM, et al. Adenovirus pneumonitis successfully treated with intravenous ribavirin. Haematologica. 1988;83:1128–9.

    Google Scholar 

  377. Jurado M, Navarro JM, Hernandez J, Molina MA. Adenovirusassociated haemorrhagic cystitis after bone marrow transplantation successfully treated with intravenous ribavirin. Bone Marrow Transplant. 1995;15:651–2.

    PubMed  CAS  Google Scholar 

  378. Wulffraat NM, Geelen SP, van Dijken PJ, de Graeff-Meeder B, Kuis W, Boven K. Recovery from adenovirus pneumonia in a severe combined immunodeficiency patient treated with intravenous ribavirin. Transplantation. 1995;59:927.

    PubMed  CAS  Google Scholar 

  379. Liles WC, Cushing H, Holt S, Bryan C, Hackman RC. Severe adenoviral nephritis following bone marrow transplantation. Successful treatment with intravenous ribavirin. Bone Marrow Transplant. 1994;14:663–4.

    Google Scholar 

  380. Murphy GF, Wood DP, McRoberts JW. Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol. 1993;149:565–6.

    PubMed  CAS  Google Scholar 

  381. Cassano WF. Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1991;7:247–8.

    PubMed  CAS  Google Scholar 

  382. Kawakami M, Ueda S, Maeda T, Karasuno T, Teshima H, Hiraoka A, Hakamura H, Tanaka K, Masaoka T. Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:485–90.

    Article  PubMed  CAS  Google Scholar 

  383. Kitabayashi A, Hirokawa M, Kuroki J, Nishinari T, Niitsu H, Miura AB. Successful vidarabine therapy for adenovirus type 11associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14:853–4.

    Article  PubMed  CAS  Google Scholar 

  384. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999;28:690–1.

    Article  PubMed  CAS  Google Scholar 

  385. Ljungman P, Lambertenghi-Deliliers G, Ribaud P, Einsele H, et al. Cidofovir for treatment of CMV and adenovirus infections in allogeneic stem cell transplant recipients. Blood. 1999;94:396a (abstract no. 1753).

    Google Scholar 

  386. Izadifar-Legrand F, Berrebi D, Faye A, Duval M, Houhou N, Freymuth F, Peuchmaur M, Vilmer E. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Blood. 1999;94:341a (abstract no. 1526).

    Google Scholar 

  387. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood. 1994;84:1689–90.

    PubMed  CAS  Google Scholar 

  388. La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:871–6.

    Article  PubMed  Google Scholar 

  389. Howard DS, Phillips IG, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29:1494–501.

    Article  PubMed  CAS  Google Scholar 

  390. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43:331–9.

    Article  PubMed  Google Scholar 

  391. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102:1114–20.

    Article  PubMed  CAS  Google Scholar 

  392. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36: 1001–8.

    Article  PubMed  CAS  Google Scholar 

  393. Erard V, Huang ML, Ferrenberg J, et al. Quantitative realtime polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation. viral load as a marker for invasive disease. Clin Infect Dis. 2007;45:958–65.

    Article  PubMed  CAS  Google Scholar 

  394. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–28.

    Article  PubMed  CAS  Google Scholar 

  395. Lee I, Barton T. Viral respiratory tract infections in transplant patients epidemiology, recognition and management. Drugs. 2007;67:1410–27.

    Google Scholar 

  396. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haemotol. 2008;143: 455–67.

    Google Scholar 

  397. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, et al. Epidemiology of respiratory syncytial virus infections in Washington DC. III. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol. 1973;98:355–64.

    PubMed  CAS  Google Scholar 

  398. Kim HW, Arrobio JO, Brandt CD, Jeffries BC, Pules G, et al. Epidemiology of respiratory syncytial virus infections in Washington DC. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol. 1973;98:216–25.

    PubMed  CAS  Google Scholar 

  399. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med. 1986;315:77–81.

    Article  PubMed  CAS  Google Scholar 

  400. Simoes EA. Respiratory syncytial virus infection. J Infect Dis. 1999;354:847–52.

    CAS  Google Scholar 

  401. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987–93.

    Article  PubMed  CAS  Google Scholar 

  402. Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–82.

    Article  PubMed  CAS  Google Scholar 

  403. Hall C, Walsh E, Long C, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163:693–8.

    Article  PubMed  CAS  Google Scholar 

  404. Henderson F, Collier A, Clyde WJ, et al. Respiratory syncytial virus infections, reinfections and immunity. N Engl J Med. 1979;300:530–4.

    Article  PubMed  CAS  Google Scholar 

  405. Hall C. Nosocomial respiratory syncytial virus infections. The “Cold War” has not ended. Clin Infect Dis. 2000;31:590–6.

    Article  PubMed  CAS  Google Scholar 

  406. Englund JA, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol. 1991;29:115–9.

    PubMed  CAS  Google Scholar 

  407. Welliver RC, Ogra PL. Immunology of respiratory viral infections. Annu Rev Med. 1988;39:147.

    Article  PubMed  CAS  Google Scholar 

  408. Taylor CE, Craft AW, Kernahan J, et al. Local antibody production and respiratory syncytial virus infection in children with leukaemia. J Med Virol. 1990;30:277–81.

    Article  PubMed  CAS  Google Scholar 

  409. Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988;109:203.

    PubMed  CAS  Google Scholar 

  410. Whimbey E, Bodey GP. Viral pneumonia in the immunocompromised adult with neoplastic disease. The role of common community respiratory viruses. Semin Respir Infect. 1992;7:122–31.

    PubMed  CAS  Google Scholar 

  411. Bowden RA. Respiratory virus infections after marrow transplant. The Fred Hutchinson Cancer Research Center experience. Am J Med. 1997;102(3A):27–30.

    Article  PubMed  CAS  Google Scholar 

  412. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751–5.

    Article  PubMed  CAS  Google Scholar 

  413. Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virusinduced acute lung injury in adult patients with bone marrow transplants. A clinical approach and review of the literature. Medicine (Baltimore). 1989;68:269–81.

    CAS  Google Scholar 

  414. Boeckh M, Gooley T, Bowden RA, Crawford S, et al. Risk factors for progression from respiratory syncytial virus (RSV) upper respiratory tract infection (URI) to pneumonia (RSV-IP) after hematopoietic stem cell transplantation. In: Programs and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. San Francisco; 1999.

    Google Scholar 

  415. Welliver RC. Pharmacotherapy of respiratory syncytial virus infection. Curr Opin Pharmacol. 2010;10:289–93.

    Article  PubMed  CAS  Google Scholar 

  416. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24–9.

    Article  PubMed  CAS  Google Scholar 

  417. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease. A prospective, double-blind, randomized clinical trial. Crit Care Med. 1994;22:566–72.

    Article  PubMed  CAS  Google Scholar 

  418. Moler FW, Steinhart CM, Ohmit SE, Stidham GL. for the Pediatric Critical Care Study Group. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr. 1996;128:422–8.

    Article  PubMed  CAS  Google Scholar 

  419. Law B, Wang EEL, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus infection? An analysis using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database. Pediatrics. 1997;99:E7.

    Article  PubMed  CAS  Google Scholar 

  420. Randolph AG, Wang EEL. Ribavirin for respiratory syncytial virus lower respiratory tract infection. Arch Pediatr Adolesc Med. 1996;150:942–7.

    Article  PubMed  CAS  Google Scholar 

  421. Adams RH, Christenson JC, Petersen FB, Beatty PG. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant. 1999;24:661–4.

    Article  PubMed  CAS  Google Scholar 

  422. Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19: 905–8.

    Article  PubMed  CAS  Google Scholar 

  423. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40:2555–7.

    PubMed  CAS  Google Scholar 

  424. McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients. Effective therapy with short duration nebulized ribavirin. Bone Marrow Transplant. 1998;21:423–5.

    Article  PubMed  CAS  Google Scholar 

  425. Boeckh M, Englund Y, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245–9.

    Article  PubMed  CAS  Google Scholar 

  426. Chemaly RF, Shubhra G, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients. Medicine. 2006;85:278–87.

    Article  PubMed  Google Scholar 

  427. Gruber WC, Wilson SZ, Throop BJ, et al. Immunoglobulin administration and ribavirin therapy. Efficacy in respiratory syncytial virus infection in the cotton rat. Pediatr Res. 1987;21:270–4.

    Article  PubMed  CAS  Google Scholar 

  428. Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:393–9.

    PubMed  CAS  Google Scholar 

  429. Connor JD, Hintz M, Van Dyke R, et al. Ribavirin pharmacokinetics in children and adults during therapeutic trials. In: Smith RA, Knight V, Smith JAD, editors. Clinical applications of ribavirin. Orlando: Academic Press; 1984. p. 107–23.

    Google Scholar 

  430. McIntosh K, Kurachek SC, Cairns LM, et al. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child. 1984;138:305–8.

    PubMed  CAS  Google Scholar 

  431. DeVincenzo JP, Hirsch RL, Fuentes RJ, et al. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experience. Bone Marrow Transplant. 2000;25:161–5.

    Article  PubMed  CAS  Google Scholar 

  432. Scott LJ, Lamb HM. Palivizumab. Drugs. 1999;58:305–11.

    Article  PubMed  CAS  Google Scholar 

  433. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduced hospitalizations from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.

    Article  Google Scholar 

  434. Boeckh M, Bowden RA, Berry MM, et al. Phase I evaluation of a RSV-specific humanized monoclonal antibody (MEDI-493) after hematopoietic stem cell transplantation (HSCT). In: Programs and Abstracts of the 28th interscience conference on antimicrobial agents and chemotherapy (San Diego, 1998).

    Google Scholar 

  435. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI 493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–24.

    Article  PubMed  CAS  Google Scholar 

  436. McCoy D, Wong E, Kuyumjian AG, et al. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis. 2011;13(2):117–21.

    Article  PubMed  CAS  Google Scholar 

  437. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases. Single-center study and review of the literature. Clin Infect Dis. 2008;46:402–12.

    Article  PubMed  CAS  Google Scholar 

  438. Avetisyan G, Mattsson J, Sparrelid E, et al. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation. A retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;10:1222–6.

    Article  Google Scholar 

  439. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR. 2000;49((No. RR-10):1–172.

    Google Scholar 

  440. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354:1277–82.

    Article  PubMed  CAS  Google Scholar 

  441. Kaiser L. Respiratory viruses in immunocompromised hosts. In: Wingard JR, Bowden RA, editors. Management of infections in oncology patients. London: Martin Dunitz; 2003.

    Google Scholar 

  442. Whimbey E, Elting LS, Cough RB, Lo W, Williams L, Champlin RE, Bodey GP. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994;13:437–40.

    PubMed  CAS  Google Scholar 

  443. Elting LS, Whimbey E, Lo W, et al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer. 1995;3:198–202.

    Article  PubMed  CAS  Google Scholar 

  444. Apalsch AM, Green M, Ledesma-Medina J, et al. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis. 1995;20:394–9.

    Article  PubMed  CAS  Google Scholar 

  445. Rabella N, Rodriguez P, Labeaga R, et al. Conventional respiratory viruses recovered from immunocompromised patients. Clinical considerations. Clin Infect Dis. 1999;28:1043–8.

    Article  PubMed  CAS  Google Scholar 

  446. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997;24:1095–9.

    Article  PubMed  CAS  Google Scholar 

  447. Centers for Disease Control and Prevention. Update. novel Influenza A (H1N1) virus infection—Mexico, March–May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:467–70.

    Google Scholar 

  448. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med. 2009;360:2616–25.

    Article  PubMed  CAS  Google Scholar 

  449. United States Centers for Disease Control and Prevention. Novel H1N1 flu situation update, 4 Sept 2009. http.//www.cdc.gov/h1n1flu/update.htm.

  450. World Health Organization. Influenza-like illness in the United States and Mexico, 24 April 2009. http.//www.who.int/csr/don/2009_04_24/en/index.html).

  451. Centers for Disease Control and Prevention. Oseltamivir-resistant novel Influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, WA, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1–4.

    Google Scholar 

  452. Choi SM, Bouderault AA, Xie H, et al. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117:5050–6.

    Article  PubMed  CAS  Google Scholar 

  453. Warner JL, Todd SJ, Shalaby H, et al. Comparison of Directigen FLU-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus. J Clin Microbiol. 1991;29:479–82.

    Google Scholar 

  454. Centers for Disease Control and Prevention. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR. 1999;48((No. RR-14):1–10.

    Google Scholar 

  455. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580–4.

    Article  PubMed  CAS  Google Scholar 

  456. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection. Treatment with rimantadine. Pediatrics. 1987;80:275–82.

    PubMed  CAS  Google Scholar 

  457. Clover RD, Crawford SA, Abell TD, et al. Effectiveness of rimantadine in prophylaxis of children within families. Am J Dis Child. 1986;140:706–9.

    PubMed  CAS  Google Scholar 

  458. Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Ann Intern Med. 1987;107:732–40.

    PubMed  CAS  Google Scholar 

  459. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26:1418–24.

    Article  PubMed  CAS  Google Scholar 

  460. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HC1 and rimantidine HC1 in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 1969;281:579.

    Article  PubMed  CAS  Google Scholar 

  461. Belshe RB, Burk B, Newman F, et al. Resistance of influenza A virus to amantadine and rimantadine. Results of one decade of surveillance. J Infect Dis. 1989;159:430–8.

    Article  PubMed  CAS  Google Scholar 

  462. Hayden FG, Couch RB. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Rev Med Virol. 1992;2:89–96.

    Article  Google Scholar 

  463. Hayden FG, Belshe RB, Clover RD, et al. Emergence of resistance and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702.

    Article  PubMed  CAS  Google Scholar 

  464. Degeleu J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390–2.

    Article  Google Scholar 

  465. Calfee DP, Hayden FG. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs. 1998;56:537–53.

    Article  PubMed  CAS  Google Scholar 

  466. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;335:827–35.

    Article  Google Scholar 

  467. Hayden FG, Osterhaus A, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 1997;337:874–80.

    Article  PubMed  CAS  Google Scholar 

  468. The MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877–81.

    Article  Google Scholar 

  469. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43.

    Article  PubMed  CAS  Google Scholar 

  470. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257–62.

    Article  PubMed  CAS  Google Scholar 

  471. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695–700.

    Article  PubMed  CAS  Google Scholar 

  472. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11:100–5.

    Article  PubMed  CAS  Google Scholar 

  473. Kobayashi S, Kimura F, Kobayashi A, et al. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother. 2008;14:308–10.

    Article  PubMed  Google Scholar 

  474. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.

    PubMed  CAS  Google Scholar 

  475. Zambon M, Bull T, Sadler CJ, et al. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol. 1998;36:2289–93.

    PubMed  CAS  Google Scholar 

  476. Whimby E, Vartivarian SE, Champlin SE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis. 1993;12:690–701.

    Article  Google Scholar 

  477. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992;325:921–6.

    Article  Google Scholar 

  478. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996;23:1033–7.

    Article  PubMed  CAS  Google Scholar 

  479. Hayden FG, Sable CA, Connor JD, et al. Intravenous ribavirin by constant infusion for serious influenza and parainfluenza infection. Antiviral Ther. 1996;1:51–6.

    CAS  Google Scholar 

  480. Dare R, Sanghavi S, Bullotta A, et al. Diagnosis of human metapneumovirus infection in immunocompromised lung transplant recipients and children evaluated for pertussis. J Clin Microbiol. 2007;45:548.

    Article  PubMed  CAS  Google Scholar 

  481. Esper F, Boucher D, Weibel C, et al. Human metapneumovirus infection in the United States. Clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics. 2003;111:1407.

    Article  PubMed  Google Scholar 

  482. Bastien N, Ward D, Van Caeseele P, et al. Human metapneumovirus infection in the Canadian population. J Clin Microbiol. 2003;41:4642.

    Article  PubMed  CAS  Google Scholar 

  483. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis. 2004;189:1388.

    Article  PubMed  Google Scholar 

  484. Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis. 2005;192:1052.

    Article  PubMed  Google Scholar 

  485. Larcher C, Geltner C, Fischer H, et al. Human metapneumovirus infection in lung transplant recipients. Clinical presentation and epidemiology. J Heart Lung Transplant. 2005;24:1891.

    Article  PubMed  Google Scholar 

  486. Englund JA, Boeckh M, Kuypers J, et al. Brief communication. Fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344.

    PubMed  Google Scholar 

  487. Debiaggi M, Canducci F, Sampaolo M, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis. 2006;194:474.

    Article  PubMed  Google Scholar 

  488. Hamlin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50:774.

    Article  CAS  Google Scholar 

  489. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart lung Transplant. 2007;26:862.

    Article  PubMed  Google Scholar 

  490. Centers for Disease Control. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR. 1999;48((No. RR-12)):1–37.

    Google Scholar 

  491. Koff RS. Hepatitis A. Lancet. 1998;351:1643–9.

    Article  PubMed  CAS  Google Scholar 

  492. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2007. MMWR. 2009;58(No. SS3).

    Google Scholar 

  493. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic Hepatitis B virus infection. MMWR. 2008;57(No. RR-8).

    Google Scholar 

  494. Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, editors. Health information for international travel 2010. Atlanta, GA: Centers for Disease Control; 2009.

    Google Scholar 

  495. Chen P, Chiou TJ, Fan FS, et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation. 1999;67:1425–33.

    Article  PubMed  CAS  Google Scholar 

  496. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers. A review of the problem. J Clin Oncol. 1999;17:394–8.

    PubMed  CAS  Google Scholar 

  497. Wands JR. Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet. 1975;2:979.

    Article  PubMed  CAS  Google Scholar 

  498. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Reports of a prospective study. Gastroenterology. 1991;100:182–8.

    PubMed  CAS  Google Scholar 

  499. Liang RH, Lok AS, Lai CL, et al. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990;8:261–70.

    Article  PubMed  CAS  Google Scholar 

  500. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med. 1989;73:911–7.

    PubMed  CAS  Google Scholar 

  501. Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma. An epidemiological study in Japan. Ann Oncol. 1997;8:S107–9.

    Article  Google Scholar 

  502. Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B carriers with hematological malignancies. Survey in Japan, 1987–1991. Cancer. 1996;78:2210–5.

    Article  PubMed  CAS  Google Scholar 

  503. Hoofnagle JH, Duskeiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447.

    PubMed  CAS  Google Scholar 

  504. Utili R, Zampino R, Bellopede P, et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors. Long-term follow-up and effect of interferon treatment. Blood. 1999;94:4046–52.

    PubMed  CAS  Google Scholar 

  505. Lau GK, Lie AK, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic stem cell transplantation. Blood. 2000;96:452–8.

    PubMed  CAS  Google Scholar 

  506. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HBsAg positive donors. A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86:3236–40.

    PubMed  CAS  Google Scholar 

  507. Lau GK, Liang RT, Chiu EK, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection. A case controlled study. Bone Marrow Transplant. 1997;19:795–9.

    Article  PubMed  CAS  Google Scholar 

  508. Caselitz M, Link H, Hein R, et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol. 1997;27:572–7.

    Article  PubMed  CAS  Google Scholar 

  509. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood. 1991;71:195–200.

    Google Scholar 

  510. Forbes GM, Davies JM, Herrmann RP, et al. Liver disease ­complicating bone marrow transplantation. A clinical audit. J Gastroenterol Hepatol. 1995;10:1–7.

    Article  PubMed  CAS  Google Scholar 

  511. Martin BA, Rowe JM, Kouides PA, et al. Hepatitis B reactivation following allogeneic bone marrow transplant. A case report and review of the literature. Bone Marrow Transplant. 1995;15:145–8.

    PubMed  CAS  Google Scholar 

  512. Webster A, Brenner MK, Prentice HG, et al. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4:207–8.

    PubMed  CAS  Google Scholar 

  513. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091–7.

    PubMed  CAS  Google Scholar 

  514. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–61.

    Article  PubMed  CAS  Google Scholar 

  515. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.

    Article  PubMed  CAS  Google Scholar 

  516. Moses SE, Lim ZY, Sudhanva M, et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol. 2006;78:1560–3.

    Article  PubMed  CAS  Google Scholar 

  517. Lai CL, Ching CK, Tung AK, et al. Lamivudine is efffective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers. A placebo-controlled trial. Hepatology. 1997;25:241–4.

    Article  PubMed  CAS  Google Scholar 

  518. Main J, Brown JL, Howells C, et al. double blind placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatol. 1996;3:211–5.

    Article  CAS  Google Scholar 

  519. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997;26:216–25.

    PubMed  CAS  Google Scholar 

  520. Clark FL, Drummond MW, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:385–7.

    Article  PubMed  CAS  Google Scholar 

  521. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–63.

    Article  PubMed  CAS  Google Scholar 

  522. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1988;339:61–8.

    Article  Google Scholar 

  523. Lau GK, McDonald GB, Strasser SI. Hepatitis virus infection in patients with cancer. In: Wingard JR, Bowden RA, editors. Management of infections in oncology patients. London: Marin Dunitz; 2003. p. 321–42.

    Google Scholar 

  524. Lalazar G, Rund D, Shouval D, et al. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.

    Article  PubMed  CAS  Google Scholar 

  525. Gilson RJ, Chopra K, Murray-Lyon IM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic ­hepatitis B virus infection. J Viral Hepatol. 1999;6:387–95.

    Article  CAS  Google Scholar 

  526. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008;22:117–26.

    Article  PubMed  CAS  Google Scholar 

  527. Dlaney IV WE, Borroto-Esoda K. Therapy of chronic hepatitis: trends and development. Curr Opin Pharmacol. 2008;8:532–40.

    Article  CAS  Google Scholar 

  528. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine. Hepatology. 1996;24:714–7.

    PubMed  CAS  Google Scholar 

  529. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997;349:20–2.

    Article  PubMed  CAS  Google Scholar 

  530. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants. Potential virological and clinical significance. Hepatology. 1998;27:294–7.

    Article  PubMed  CAS  Google Scholar 

  531. Greenberg HB, Pollard RB, Lutwixk LI, et al. Effect of human leukocyte interferon on hepatitis B virus infection on patients with chronic active hepatitis. N Engl J Med. 1976;295:517.

    Article  PubMed  CAS  Google Scholar 

  532. Rosendahl C, Bender-Götze Ch, Deinhardt F, Kolb H-J, Haas R. Immunization against hepatitis B in BMT and leukemia patients. Exp Hematol. 1985;13:104.

    Google Scholar 

  533. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology. 1993;104:1818–21.

    PubMed  CAS  Google Scholar 

  534. Shouval D, Adler R, Ilan Y. Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology. 1993;17:955–9.

    Article  PubMed  CAS  Google Scholar 

  535. Schreiber GP, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med. 1993;334: 1691–6.

    Google Scholar 

  536. Donahue JG, Munoz A, Ness PM, et al. The declining risk of posttransfusion hepatitis C virus infection. N Engl J Med. 1992;327: 369–73.

    Article  PubMed  CAS  Google Scholar 

  537. Armstrong GL, Wasley AM, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.

    PubMed  Google Scholar 

  538. DiBisceglie AM. Hepatitis C. Lancet. 1998;351:351–5.

    Article  CAS  Google Scholar 

  539. Shakil A, Conry-Cantilena C, Alter H, et al. Volunteer blood donors with antibody to hepatitis C virus. Clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med. 1995;23:330–7.

    Google Scholar 

  540. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;328:465–70.

    Article  PubMed  CAS  Google Scholar 

  541. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47((No. RR-19)):1–40.

    Google Scholar 

  542. Paul IM, Sanders J, Ruggerio F, et al. Chronic hepatitis C virus infections in leukemia survivors. Prevalence, viral load, and severity of liver disease. Blood. 1999;93:3672–7.

    PubMed  CAS  Google Scholar 

  543. Arico M, Maggiore G, Silini E, et al. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood. 1994;84:2919–22.

    PubMed  CAS  Google Scholar 

  544. Lopez-Jimenez J, Cancelas JA, Garcia-Larana J, et al. Posttransfusion hepatitis after induction chemotherapy in acute nonlymphoblastic leukemia. Implications for long-term management and outcome. Transfusion. 1995;35:313–8.

    Article  PubMed  CAS  Google Scholar 

  545. Meilson JR, Harrison P, Skidmore SJ, et al. Chronic hepatitis C in long-term survivors of haematological malignancy treated in a single centre. J Clin Pathol. 1996;49:230–2.

    Article  Google Scholar 

  546. Murphy MF, Waters AH, Grint PC, et al. Hepatitis C infection in multitransfused patients with acute leukaemia. Lancet. 1990;335:58–9.

    Article  PubMed  CAS  Google Scholar 

  547. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood. 1997;90:4628–33.

    PubMed  CAS  Google Scholar 

  548. Fujii Y, Kaku K, Tanaka M, et al. Hepatitis C virus infection in patients with leukemia. Am J Hematol. 1994;46:278–82.

    Article  PubMed  CAS  Google Scholar 

  549. Stickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood. 2000;95:3065–70.

    Google Scholar 

  550. Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86:1614–8.

    PubMed  CAS  Google Scholar 

  551. Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation. Transplantation. 1991;52:315–8.

    Article  PubMed  CAS  Google Scholar 

  552. Jackson SR, Carter JM, Jackson TW, et al. Hepatitis C seroprevalance in bone marrow transplant recipients and hemophiliacs. N Z Med J. 1994;107:10–1.

    PubMed  CAS  Google Scholar 

  553. Fujii Y, Kaku K, Tanaka M, et al. Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;13:523–6.

    PubMed  CAS  Google Scholar 

  554. Schuhart MC, Myerson D, Spurgeon CL, et al. Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. Bone Marrow Transplant. 1996;17:601–6.

    Google Scholar 

  555. Schuhart MC, Myerson D, Childs BH, et al. Marrow transplantation from hepatitis C virus seropositive donors. Transmission rate and clinical course. Blood. 1994;84:3229–35.

    Google Scholar 

  556. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation. A cohort study with 10 year follow-up. Hepatology. 1999;29:1893–9.

    Article  PubMed  CAS  Google Scholar 

  557. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83:1998–2004.

    PubMed  CAS  Google Scholar 

  558. Ljungman P, Hagglund H, Lonnqvist B, et al. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver (letter). Blood. 1994;84:1349–50.

    PubMed  CAS  Google Scholar 

  559. Norol F, Roche B, Girardin MF, et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation. 1994;57:393–7.

    Article  PubMed  CAS  Google Scholar 

  560. Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16: 407–11.

    PubMed  CAS  Google Scholar 

  561. Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86:1614–8.

    PubMed  CAS  Google Scholar 

  562. Tomas JF, Pinilla I, Garcia-Buey ML, Garcıa A, Figuera A, de Soria VGG Gomez-Garcıa, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation. Clinical features and course in 61 patients. Bone Marrow Transplant. 2000;26:649–55.

    Article  PubMed  CAS  Google Scholar 

  563. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection and bone marrow transplantation. A cohort study with 10-year follow-up. Hepatology. 1999;29:1893–9.

    Article  PubMed  CAS  Google Scholar 

  564. Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG, et al. Cirrhosis of the in long-term marrow transplant survivors. Blood. 1999;93:3259–66.

    PubMed  CAS  Google Scholar 

  565. Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–24.

    Article  PubMed  CAS  Google Scholar 

  566. Ivantes CA, Amarante H, Ioshii SO, Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004;33:1181–5.

    Article  PubMed  CAS  Google Scholar 

  567. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation. a study of 193 patients. Blood. 2004;103:78–84.

    Article  PubMed  CAS  Google Scholar 

  568. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 1989;321:1501–6.

    Article  PubMed  CAS  Google Scholar 

  569. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–10.

    Article  PubMed  Google Scholar 

  570. Makris M, Preston FE, Triger DR, et al. A randomized trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs. Blood. 1991;78:1672–7.

    PubMed  CAS  Google Scholar 

  571. Hoofnagle JH, di Bisceglie AM. Drug therapy. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347–56.

    Article  PubMed  CAS  Google Scholar 

  572. Lindsay KL. Therapy of hepatitis C. Overview. Hepatology. 1997;26:S71–7.

    Article  Google Scholar 

  573. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter study group. N Engl J Med. 1995;332:1457–62.

    Article  PubMed  CAS  Google Scholar 

  574. Carithers Jr RL, Emerson SS. Therapy of hepatitis C. Meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26:83S–8.

    Article  PubMed  CAS  Google Scholar 

  575. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet. 1998;352:1426–32.

    Article  PubMed  CAS  Google Scholar 

  576. Reichard O, Norkrans G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83–7.

    Article  PubMed  CAS  Google Scholar 

  577. Schvarcz R, Yun ZB, Sonnerborg A, et al. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol. 1995;46:43–7.

    Article  PubMed  CAS  Google Scholar 

  578. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.

    Article  PubMed  CAS  Google Scholar 

  579. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  PubMed  CAS  Google Scholar 

  580. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394–401.

    PubMed  CAS  Google Scholar 

  581. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981–90.

    PubMed  CAS  Google Scholar 

  582. Hehlmann R, Hochhaus A, Kolb HJ, et al. Interferon alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668–77.

    PubMed  CAS  Google Scholar 

  583. DiBisceglie AM, Shindoi M, Fong TL, et al. A pilot study of ribavirin for chronic hepatitis C. Hepatology. 1992;16:649–54.

    Article  CAS  Google Scholar 

  584. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C. Results of a placebo-controlled study. J Hepatol. 1996;25:591–8.

    Article  PubMed  CAS  Google Scholar 

  585. Bodenheimer Jr HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial. Hepatology. 1997;26:473–7.

    Article  PubMed  CAS  Google Scholar 

  586. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C. Interferon and ribavirin. Hepatology. 1997;26 Suppl 1:108S–11.

    Article  PubMed  CAS  Google Scholar 

  587. Ljungman P, Andersson J, Aschan J, et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis. 1996;23:167–9.

    Article  PubMed  CAS  Google Scholar 

  588. Shuhart MC, Myerson D, Childs BH, et al. Marrow transplantation from hepatitis C virus seropositive donors. Transmission rate and clinical course. Blood. 1994;84:3229–35.

    PubMed  CAS  Google Scholar 

  589. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 1997;158:1473–81.

    PubMed  CAS  Google Scholar 

  590. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286–90.

    Article  PubMed  CAS  Google Scholar 

  591. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201–5.

    PubMed  CAS  Google Scholar 

  592. Linnen J, Wages JR, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus. A transfusion-transmissible agent. Science. 1996;271:505–8.

    Article  PubMed  CAS  Google Scholar 

  593. Leary TP, Muerhoff AS, Simons JN, et al. Sequence and genomic organization of GBV-C. A novel member of the faviviridae associated with human non-A–E hepatitis. J Med Virol. 1996;48:60–7.

    Article  PubMed  CAS  Google Scholar 

  594. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med. 1995;1:564–9.

    Article  PubMed  CAS  Google Scholar 

  595. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J Med Virol. 1996;50:97–103.

    Article  PubMed  CAS  Google Scholar 

  596. Yoshikawa A, Fukuda S, Itoh K, et al. Infection with hepatitis G virus and its strain variant, the GB agent (GBV-C) among blood donors in Japan. Transfusion. 1997;37:657–63.

    Article  PubMed  CAS  Google Scholar 

  597. Yamada-Osaki M, Sumazaki R, Tsuchida M, et al. Persistence and clinical outcome of hepatitis G virus-infection in pediatric bone marrow transplant recipients and children treated for hematological malignancy. Blood. 1999;93:721–7.

    PubMed  CAS  Google Scholar 

  598. Akiyama H, Nakamura N, Tanikawa S, et al. Incidence and influence of GB virus C and hepatitis C virus infection in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1998;21:1131–5.

    Article  PubMed  CAS  Google Scholar 

  599. Skidmore SJ, Collingham KE, Harrison P, et al. High prevalence of hepatitis G virus in bone marrow transplant recipients and patients treated for acute leukemia. Blood. 1997;89:3853–6.

    PubMed  CAS  Google Scholar 

  600. Rodriguez-Inigo E, Tomas JF, Gomez-Garcia de Soria V, et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation. Results from a prospective study. Blood. 1997;90:1326–31.

    PubMed  CAS  Google Scholar 

  601. Corbi C, Traineau R, Esperou H, et al. Prevalence and clinical features of hepatitis G infection in bone marrow allografts recipients. Bone Marrow Transplant. 1997;20:965–8.

    Article  PubMed  CAS  Google Scholar 

  602. Kanda Y, Chiba S, Suzuki T, et al. Quantitation of hepatitis G virus RNA in allogeneic bone marrow transplant recipients. Br J Hematol. 1998;100:797–800.

    Article  Google Scholar 

  603. Neilson J, Harrison P, Milligan DW, et al. Hepatitis G virus in long-term survivors of haematological malignancy. Lancet. 1996;347:1632–3.

    Article  PubMed  CAS  Google Scholar 

  604. Ljungman P, Halasz R, Hagglund H, et al. Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22:499–501.

    Article  PubMed  CAS  Google Scholar 

  605. Grinnell BW, Padgett BL, Walker DL. Distribution of non-integrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. J Infect Dis. 1983;147:669.

    Article  PubMed  CAS  Google Scholar 

  606. Hogan TF, Borden EC, McBain JA, et al. Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med. 1980;2:373.

    Google Scholar 

  607. Narayan O, Penney Jr JM, Johnson RT, et al. Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med. 1973;289:1278.

    Article  PubMed  CAS  Google Scholar 

  608. Saad ED, Thomas DA, O’Brien S, et al. Progressive multifocal leukoencephalopathy with concurrent Richter’s syndrome. Leuk Lymphoma. 2000;38:183–90.

    PubMed  CAS  Google Scholar 

  609. Seong D, Bruner JM, Lee KH, et al. Progressive mutlifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis. 1996;23:402–3.

    Article  PubMed  CAS  Google Scholar 

  610. Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med. 1986;315:230–4.

    Article  PubMed  CAS  Google Scholar 

  611. Russell SJ, Vowels MR, Vale T. Haemorrhagic cystitis in paediatric bone marrow transplant patients. An association with infective agents, GVHD and prior cyclophosphamide. Bone Marrow Transplant. 1994;13:533–9.

    PubMed  CAS  Google Scholar 

  612. Azzi A, Fanci R, Bosi A, et al. Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction. An approach to assess the relationship between BK viruria and hemorrhagic cystitis. Bone Marrow Transplant. 1994;14:235–40.

    PubMed  CAS  Google Scholar 

  613. Schneider EM, Dörries K. High frequency of polyomavirus infection in lymphoid cell preparations after allogeneic bone marrow transplantation. Transplant Proc. 1993;25:1271–3.

    PubMed  CAS  Google Scholar 

  614. Azzi A, Cesaro S, Laszlo D, et al. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol. 1999;14:79–86.

    Article  PubMed  CAS  Google Scholar 

  615. Drummond JE, Shah KV, Saral R, Santos GW, Donnenberg AD. BK virus specific humoral and cell mediated immunity in allogeneic bone marrow transplant (BMT) recipients. J Med Virol. 1987;23:331–44.

    Article  PubMed  CAS  Google Scholar 

  616. Torok TJ. Parvovirus B19 and human disease. Adv Intern Med. 1992;37:431–55.

    PubMed  CAS  Google Scholar 

  617. Coulombel L, Morinet F, Mielot F, et al. Parvovirus infection, leukemia, and immunodeficiency. Lancet. 1989;1:101–2.

    Article  Google Scholar 

  618. Smith MA, Shah NR, Lobel JS, et al. Severe anemia caused by human parvovirus in a leukemia patient on maintenance chemotherapy. Clin Pediatr. 1988;27:383–6.

    Article  CAS  Google Scholar 

  619. Fisher D, Spencer D, Iland H, et al. Red cell aplasia caused by human parvovirus B19 in acute leukaemia. Aust N Z J Med. 1992;22:303–4.

    Article  PubMed  CAS  Google Scholar 

  620. Van Horn DK, Mortimer PP, Young N, et al. Human parvovirusassociated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol. 1986;8:235–9.

    Article  PubMed  Google Scholar 

  621. Allen-Graeve JL, de Alarcon PA, Naides SJ. Parvovirus B19 infection in patients receiving cancer chemotherapy. The expanding spectrum of disease. Am J Pediatr Hematol Oncol. 1989;11:441–4.

    Google Scholar 

  622. Frickhofen N, Arnold R, Hertenstein B, et al. Parvovirus B19 infection and bone marrow transplantation. Ann Hematol. 1992;64:A121–4.

    Article  PubMed  Google Scholar 

  623. Broliden K, Tolfvenstam T, Ohlsson S, et al. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol. 1998;31:66–72.

    Article  PubMed  CAS  Google Scholar 

  624. Mihal V, Dusek J, Hajduch M, et al. Transient aplastic crisis in a leukemic child caused by parvovirus B19 infection. Pediatr Hematol Oncol. 1996;13:173–7.

    Article  PubMed  CAS  Google Scholar 

  625. Crook TW, Rogers BB, McFarland RD, et al. Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients. Hum Pathol. 2000;31:161–8.

    Article  PubMed  CAS  Google Scholar 

  626. Antin JH, Smith BR, Ewenstein BM, et al. HTLV-III infection after bone marrow transplantation. Blood. 1986;67:160–3.

    PubMed  CAS  Google Scholar 

  627. Centers for Disease Control (CDC). Opportunistic non-Hodgkin’s lymphomas among severely immunocompromised HIV-infected patients surviving for prolonged periods on antiretroviral therapy—United States. MMWR. 1991;40:591; 597–600.

    Google Scholar 

  628. Rabkin CS, Hilgartner MW, Hedberg KW, et al. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA. 1992;267:1090–4.

    Article  PubMed  CAS  Google Scholar 

  629. Beral V, Peterman T, Berkelmam R, Jaffe H. AIDS-associated nonHodgkin’s lymphoma. Lancet. 1991;337:805–9.

    Article  PubMed  CAS  Google Scholar 

  630. Gail MH, Pluda JM, Rabkin CS, et al. Projections of the incidence of non-Hodgkin’s lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst. 1991;83:695–701.

    Article  PubMed  CAS  Google Scholar 

  631. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation and azido-thymidine. Effects on HIV-1 in a patient with non-Hodgkin’s lymphoma. Ann Intern Med. 1989;111:973–81.

    PubMed  CAS  Google Scholar 

  632. Saral R, Holland HK. bone marrow transplantation for the acquired immune deficiency syndrome. In: Forman SJ, Blume KG, Thomas ED, editors. bone marrow transplant. Boston: Blackwell Scientific Publications; 1994. p. 654–64.

    Google Scholar 

  633. Contu L, La Nasa G, Arras M, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. 1993;12:669–71.

    PubMed  CAS  Google Scholar 

  634. Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96: 2730–4.

    PubMed  CAS  Google Scholar 

  635. Porcu P, Caligiuri MA. Acquired immunodeficiency syndromerelated lymphomas. Future directions. Semin Oncol. 2000;27: 454–62.

    PubMed  CAS  Google Scholar 

  636. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies. Implications for clinical management. JAMA. 2000; 284:223–8.

    Article  PubMed  CAS  Google Scholar 

  637. Aviles A, Halabe J. Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma. Cancer Biother Radiopharm. 1999;14:349–52.

    Article  PubMed  CAS  Google Scholar 

  638. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2000;12:438–44.

    Article  PubMed  CAS  Google Scholar 

  639. Okenhendler E, Gerard L, Dubreuil ML, et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated nonHodgkin’s lymphoma. Leuk Lymphoma. 2000;39:87–95.

    Article  Google Scholar 

  640. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma. AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59–66.

    Article  PubMed  CAS  Google Scholar 

  641. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000;355:1071–2.

    Article  PubMed  CAS  Google Scholar 

  642. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer. 2000;89: 680–9.

    Article  PubMed  CAS  Google Scholar 

  643. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98:3857–9.

    Article  PubMed  CAS  Google Scholar 

  644. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–7.

    Article  PubMed  CAS  Google Scholar 

  645. Gupta V, Tomblyn M, Pederson T, et al. Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with hematologic disorders. a report from the center for international blood and marrow transplant research (CIBMTR). Biol Blood Marrow Transplant. 2009;15(7):864–71.

    Article  PubMed  Google Scholar 

  646. Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res. 1989;49:226.

    PubMed  CAS  Google Scholar 

  647. Ratner L, Griffith RC, Marselle L, et al. A lymphoproliferative disorder caused by human T-lymphotropic virus type I. Am J Med. 1987;83:953–8.

    Article  PubMed  CAS  Google Scholar 

  648. Tsukasaki K, Hermine O, Bazarbachi A. Definition, prognostic factors, treatment, and response criteria of adult t-cell leukemia-lymphoma. A proposal from an international consensus meeting. J Clin Oncol. 2008;27:453–9.

    Article  PubMed  Google Scholar 

  649. Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobin products. J Infect Dis. 2007;196:435.

    Article  PubMed  Google Scholar 

  650. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807.

    Article  PubMed  CAS  Google Scholar 

  651. Ferguson DD, Gershman K, LeBailly A, et al. Characteristics of the rash associated with West Nile virus fever. Clin Infect Dis. 2005;41:1204.

    Article  PubMed  Google Scholar 

  652. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617.

    Article  PubMed  Google Scholar 

  653. Bode AV, Sejvar JJ, Pape J, et al. West Nile virus disease. A descriptive study of 228 patents hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006;42:1234.

    Article  PubMed  Google Scholar 

  654. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290:511.

    Article  PubMed  Google Scholar 

  655. Paddock CD, Nicholson WL, Bhatnager J, et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis. 2006;42:1527.

    Article  PubMed  Google Scholar 

  656. Hiatt B, Desjardin L, Carter T, et al. A fatal case of West Nile virus infection in a bone marrow transplant recipient. Clin Infect Dis. 2003;37:e129.

    Article  PubMed  Google Scholar 

  657. DeSalvo D, Roy-Chaudhury P, Peddi R, et al. West Nile virus encephalitis in organ transplant recipients. Another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466.

    Article  PubMed  Google Scholar 

  658. Tilley PA, Fox JD, Jayaraman GC, et al. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis. 2006;193:1361.

    Article  PubMed  CAS  Google Scholar 

  659. Hong DS, Jacobson KL, Raad II, et al. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients. Case series and literature review. Clin Infect Dis. 2003;37:1044.

    Article  PubMed  Google Scholar 

  660. Gea-Banacloche J, Johnson RT, Bagic A, et al. West Nile virus. Pathogenesis and therapeutic options. Ann Intern Med. 2004;140:545.

    PubMed  Google Scholar 

  661. Jordan I, Briese T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 2000;182:1214.

    Article  PubMed  CAS  Google Scholar 

  662. Hamden A, Green P, Mendelson E, et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis. 2002;4:160.

    Article  Google Scholar 

  663. Ben-Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5.

    Article  PubMed  CAS  Google Scholar 

  664. Centers for Disease Control and Prevention. Possible dialysis related West Nile virus transmission-Georgia, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:738.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, University of Florida, 1600 SW Archer Road, 100277, Gainesville, FL, USA

    Jack W. Hsu M.D. & John W. Hiemenz M.D.

  2. Division of Hematology/Oncology, Department of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL, 32610, USA

    John R. Wingard M.D.

  3. Division of Hematology/Oncology, Department of Medicine, University of Florida, 9320 SW 46th Place, Gainesville, FL, 32608-7111, USA

    Helen Leather B.Pharm

Authors
  1. Jack W. Hsu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Hiemenz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John R. Wingard M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen Leather B.Pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack W. Hsu M.D. .

Editor information

Editors and Affiliations

  1. Beth Israel Hospital, Cancer Center, St. Lukes-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Peter H. Wiernik

  2. , Department of Hematology, Imperial College of London, Du Cane Road 150, London, W12 0NN, United Kingdom

    John M. Goldman

  3. Continuum Cancer Centers, Department of Medicine, St. Luke's-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Janice P. Dutcher

  4. , Division of Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Robert A. Kyle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hsu, J.W., Hiemenz, J.W., Wingard, J.R., Leather, H. (2013). Viral Infections in Patients with Hematological Malignancies. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_53

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3764-2_53

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3763-5

  • Online ISBN: 978-1-4614-3764-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation